SG195572A1 - Methods and systems for evaluating memory agents - Google Patents
Methods and systems for evaluating memory agents Download PDFInfo
- Publication number
- SG195572A1 SG195572A1 SG2013077730A SG2013077730A SG195572A1 SG 195572 A1 SG195572 A1 SG 195572A1 SG 2013077730 A SG2013077730 A SG 2013077730A SG 2013077730 A SG2013077730 A SG 2013077730A SG 195572 A1 SG195572 A1 SG 195572A1
- Authority
- SG
- Singapore
- Prior art keywords
- branched
- alkyl
- stimuli
- straight chained
- subject
- Prior art date
Links
- 230000015654 memory Effects 0.000 title claims abstract description 219
- 238000000034 method Methods 0.000 title claims abstract description 191
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 147
- 238000012549 training Methods 0.000 claims abstract description 132
- 238000012360 testing method Methods 0.000 claims abstract description 108
- 150000001875 compounds Chemical class 0.000 claims abstract description 67
- 229940000406 drug candidate Drugs 0.000 claims abstract description 9
- 125000000217 alkyl group Chemical group 0.000 claims description 201
- 125000003118 aryl group Chemical group 0.000 claims description 150
- 241001465754 Metazoa Species 0.000 claims description 148
- -1 methylenedioxy group Chemical group 0.000 claims description 142
- 102000005636 Cyclic AMP Response Element-Binding Protein Human genes 0.000 claims description 120
- 108010045171 Cyclic AMP Response Element-Binding Protein Proteins 0.000 claims description 120
- 230000004044 response Effects 0.000 claims description 73
- 230000007787 long-term memory Effects 0.000 claims description 62
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 58
- 125000001072 heteroaryl group Chemical group 0.000 claims description 50
- 241000282414 Homo sapiens Species 0.000 claims description 41
- 125000003342 alkenyl group Chemical group 0.000 claims description 34
- 241000288906 Primates Species 0.000 claims description 33
- 125000000304 alkynyl group Chemical group 0.000 claims description 32
- 241000124008 Mammalia Species 0.000 claims description 30
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 30
- 230000037361 pathway Effects 0.000 claims description 30
- 125000004432 carbon atom Chemical group C* 0.000 claims description 29
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 29
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 29
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 21
- 229910052757 nitrogen Inorganic materials 0.000 claims description 20
- 125000000335 thiazolyl group Chemical group 0.000 claims description 20
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 18
- 239000003695 memory enhancer Substances 0.000 claims description 18
- 150000003839 salts Chemical class 0.000 claims description 17
- 229910052799 carbon Inorganic materials 0.000 claims description 16
- 241000282553 Macaca Species 0.000 claims description 13
- 241000282693 Cercopithecidae Species 0.000 claims description 12
- 241000288904 Lemur Species 0.000 claims description 11
- 125000005605 benzo group Chemical group 0.000 claims description 11
- 125000005545 phthalimidyl group Chemical group 0.000 claims description 11
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 claims description 11
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims description 10
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 claims description 10
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims description 10
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 claims description 10
- 125000002541 furyl group Chemical group 0.000 claims description 10
- 125000002883 imidazolyl group Chemical group 0.000 claims description 10
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims description 10
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 claims description 10
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 claims description 10
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims description 10
- 125000001786 isothiazolyl group Chemical group 0.000 claims description 10
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 10
- 125000001715 oxadiazolyl group Chemical group 0.000 claims description 10
- 125000002971 oxazolyl group Chemical group 0.000 claims description 10
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 claims description 10
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 10
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 10
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 10
- 125000004076 pyridyl group Chemical group 0.000 claims description 10
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 10
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 10
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims description 10
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 10
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims description 10
- 125000001113 thiadiazolyl group Chemical group 0.000 claims description 10
- 125000001544 thienyl group Chemical group 0.000 claims description 10
- 125000004306 triazinyl group Chemical group 0.000 claims description 10
- 125000001425 triazolyl group Chemical group 0.000 claims description 10
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 9
- 238000011156 evaluation Methods 0.000 claims description 9
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 9
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 8
- 229910052760 oxygen Inorganic materials 0.000 claims description 7
- 101150005409 Pmch gene Proteins 0.000 claims description 5
- 101150024647 mch gene Proteins 0.000 claims description 5
- 101000617818 Homo sapiens Solute carrier organic anion transporter family member 4A1 Proteins 0.000 claims 1
- 102100022004 Solute carrier organic anion transporter family member 4A1 Human genes 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 abstract description 7
- 230000006735 deficit Effects 0.000 abstract description 3
- 230000006993 memory improvement Effects 0.000 abstract 1
- 230000001537 neural effect Effects 0.000 description 54
- 125000003545 alkoxy group Chemical group 0.000 description 42
- 230000014759 maintenance of location Effects 0.000 description 42
- 230000006870 function Effects 0.000 description 38
- 125000005843 halogen group Chemical group 0.000 description 34
- 238000011282 treatment Methods 0.000 description 33
- 230000007774 longterm Effects 0.000 description 31
- 239000003981 vehicle Substances 0.000 description 31
- 230000001419 dependent effect Effects 0.000 description 30
- 229940079593 drug Drugs 0.000 description 29
- 239000003814 drug Substances 0.000 description 29
- 230000000694 effects Effects 0.000 description 25
- 108090000623 proteins and genes Proteins 0.000 description 24
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 23
- 238000005259 measurement Methods 0.000 description 22
- 230000013016 learning Effects 0.000 description 21
- 125000002252 acyl group Chemical group 0.000 description 20
- 150000007523 nucleic acids Chemical group 0.000 description 19
- 230000015572 biosynthetic process Effects 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 17
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 16
- 230000014509 gene expression Effects 0.000 description 15
- 229910052739 hydrogen Inorganic materials 0.000 description 15
- 239000001257 hydrogen Substances 0.000 description 14
- 210000004556 brain Anatomy 0.000 description 13
- 230000002354 daily effect Effects 0.000 description 11
- 210000002569 neuron Anatomy 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- 230000000946 synaptic effect Effects 0.000 description 11
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 10
- 241000700159 Rattus Species 0.000 description 10
- 208000006011 Stroke Diseases 0.000 description 10
- 230000001976 improved effect Effects 0.000 description 10
- 230000006872 improvement Effects 0.000 description 9
- 102000039446 nucleic acids Human genes 0.000 description 9
- 108020004707 nucleic acids Proteins 0.000 description 9
- 210000000130 stem cell Anatomy 0.000 description 9
- 238000013518 transcription Methods 0.000 description 9
- 230000035897 transcription Effects 0.000 description 9
- 101100027969 Caenorhabditis elegans old-1 gene Proteins 0.000 description 8
- 208000026139 Memory disease Diseases 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 8
- 108091028043 Nucleic acid sequence Proteins 0.000 description 8
- 125000004423 acyloxy group Chemical group 0.000 description 8
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 8
- 230000008859 change Effects 0.000 description 8
- 125000001153 fluoro group Chemical group F* 0.000 description 8
- 230000005923 long-lasting effect Effects 0.000 description 8
- 206010027175 memory impairment Diseases 0.000 description 8
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 8
- 230000006403 short-term memory Effects 0.000 description 8
- 229960005080 warfarin Drugs 0.000 description 8
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 7
- 241000700605 Viruses Species 0.000 description 7
- 150000001413 amino acids Chemical group 0.000 description 7
- 125000004429 atom Chemical group 0.000 description 7
- 230000003542 behavioural effect Effects 0.000 description 7
- 108020001507 fusion proteins Proteins 0.000 description 7
- 102000037865 fusion proteins Human genes 0.000 description 7
- 125000000623 heterocyclic group Chemical group 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 230000004911 positive regulation of CREB transcription factor activity Effects 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 241000894007 species Species 0.000 description 7
- 230000000007 visual effect Effects 0.000 description 7
- 241000255925 Diptera Species 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 230000032683 aging Effects 0.000 description 6
- 125000002877 alkyl aryl group Chemical group 0.000 description 6
- 125000001188 haloalkyl group Chemical group 0.000 description 6
- 230000006698 induction Effects 0.000 description 6
- 230000007334 memory performance Effects 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 6
- 125000001424 substituent group Chemical group 0.000 description 6
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 230000014616 translation Effects 0.000 description 6
- 108700007837 A-CREB Proteins 0.000 description 5
- 208000024827 Alzheimer disease Diseases 0.000 description 5
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 5
- 102000030621 adenylate cyclase Human genes 0.000 description 5
- 108060000200 adenylate cyclase Proteins 0.000 description 5
- 210000003169 central nervous system Anatomy 0.000 description 5
- 230000001149 cognitive effect Effects 0.000 description 5
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 210000001320 hippocampus Anatomy 0.000 description 5
- 150000002431 hydrogen Chemical group 0.000 description 5
- 125000002950 monocyclic group Chemical group 0.000 description 5
- 230000002018 overexpression Effects 0.000 description 5
- 238000001243 protein synthesis Methods 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 230000000638 stimulation Effects 0.000 description 5
- 239000013598 vector Substances 0.000 description 5
- 101710141638 Adenylate cyclase 1 Proteins 0.000 description 4
- 102100039677 Adenylate cyclase type 1 Human genes 0.000 description 4
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 4
- 101000919269 Homo sapiens cAMP-responsive element modulator Proteins 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 108700008625 Reporter Genes Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 108700019146 Transgenes Proteins 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 210000004727 amygdala Anatomy 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 4
- 208000029028 brain injury Diseases 0.000 description 4
- 102100029387 cAMP-responsive element modulator Human genes 0.000 description 4
- 239000004202 carbamide Substances 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 239000012636 effector Substances 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 230000002045 lasting effect Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 4
- 230000003956 synaptic plasticity Effects 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 230000001052 transient effect Effects 0.000 description 4
- MSYGAHOHLUJIKV-UHFFFAOYSA-N 3,5-dimethyl-1-(3-nitrophenyl)-1h-pyrazole-4-carboxylic acid ethyl ester Chemical compound CC1=C(C(=O)OCC)C(C)=NN1C1=CC=CC([N+]([O-])=O)=C1 MSYGAHOHLUJIKV-UHFFFAOYSA-N 0.000 description 3
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 239000005089 Luciferase Substances 0.000 description 3
- 241000255588 Tephritidae Species 0.000 description 3
- 102000011017 Type 4 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 description 3
- 108010037584 Type 4 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 description 3
- 239000012190 activator Substances 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 125000001246 bromo group Chemical group Br* 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 125000000000 cycloalkoxy group Chemical group 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 238000001647 drug administration Methods 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 230000000971 hippocampal effect Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 208000028867 ischemia Diseases 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 230000003340 mental effect Effects 0.000 description 3
- 230000004770 neurodegeneration Effects 0.000 description 3
- 208000015122 neurodegenerative disease Diseases 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 230000008521 reorganization Effects 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 description 3
- 210000000225 synapse Anatomy 0.000 description 3
- 125000005505 thiomorpholino group Chemical group 0.000 description 3
- 230000002103 transcriptional effect Effects 0.000 description 3
- 244000208874 Althaea officinalis Species 0.000 description 2
- 235000006576 Althaea officinalis Nutrition 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 241000237967 Aplysia Species 0.000 description 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 2
- 206010003805 Autism Diseases 0.000 description 2
- 208000020706 Autistic disease Diseases 0.000 description 2
- 208000003174 Brain Neoplasms Diseases 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 201000010374 Down Syndrome Diseases 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical group C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 206010019196 Head injury Diseases 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 208000023105 Huntington disease Diseases 0.000 description 2
- 241000713666 Lentivirus Species 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 108010043958 Peptoids Proteins 0.000 description 2
- 229940099471 Phosphodiesterase inhibitor Drugs 0.000 description 2
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 2
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical group C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- 244000088415 Raphanus sativus Species 0.000 description 2
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 description 2
- 206010039281 Rubinstein-Taybi syndrome Diseases 0.000 description 2
- 206010039966 Senile dementia Diseases 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 2
- 150000001336 alkenes Chemical class 0.000 description 2
- 125000003282 alkyl amino group Chemical group 0.000 description 2
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 2
- 125000003368 amide group Chemical group 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 210000003484 anatomy Anatomy 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 125000004104 aryloxy group Chemical group 0.000 description 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 2
- 230000003190 augmentative effect Effects 0.000 description 2
- 125000002527 bicyclic carbocyclic group Chemical group 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 230000011496 cAMP-mediated signaling Effects 0.000 description 2
- 125000002837 carbocyclic group Chemical group 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 208000015114 central nervous system disease Diseases 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 230000009850 completed effect Effects 0.000 description 2
- 230000003750 conditioning effect Effects 0.000 description 2
- 230000001054 cortical effect Effects 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 241001493065 dsRNA viruses Species 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 230000000494 facilitatory effect Effects 0.000 description 2
- 230000009395 genetic defect Effects 0.000 description 2
- 230000036433 growing body Effects 0.000 description 2
- 125000004438 haloalkoxy group Chemical group 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 150000002466 imines Chemical class 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 150000008040 ionic compounds Chemical class 0.000 description 2
- 150000002576 ketones Chemical group 0.000 description 2
- 239000008176 lyophilized powder Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 235000001035 marshmallow Nutrition 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000007074 memory dysfunction Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 125000002757 morpholinyl group Chemical group 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 150000002894 organic compounds Chemical class 0.000 description 2
- 239000013110 organic ligand Substances 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 125000003386 piperidinyl group Chemical group 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 208000020016 psychiatric disease Diseases 0.000 description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 2
- 239000000018 receptor agonist Substances 0.000 description 2
- 229940044601 receptor agonist Drugs 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- HJORMJIFDVBMOB-UHFFFAOYSA-N rolipram Chemical compound COC1=CC=C(C2CC(=O)NC2)C=C1OC1CCCC1 HJORMJIFDVBMOB-UHFFFAOYSA-N 0.000 description 2
- 229950005741 rolipram Drugs 0.000 description 2
- 201000000980 schizophrenia Diseases 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- 230000002123 temporal effect Effects 0.000 description 2
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- 125000006701 (C1-C7) alkyl group Chemical group 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 102000001707 3',5'-Cyclic-AMP Phosphodiesterases Human genes 0.000 description 1
- 108010054479 3',5'-Cyclic-AMP Phosphodiesterases Proteins 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 108060003345 Adrenergic Receptor Proteins 0.000 description 1
- 102000017910 Adrenergic receptor Human genes 0.000 description 1
- 241000710929 Alphavirus Species 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000714230 Avian leukemia virus Species 0.000 description 1
- 241001485018 Baboon endogenous virus Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000714266 Bovine leukemia virus Species 0.000 description 1
- RZZPDXZPRHQOCG-OJAKKHQRSA-O CDP-choline(1+) Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OCC[N+](C)(C)C)O[C@H]1N1C(=O)N=C(N)C=C1 RZZPDXZPRHQOCG-OJAKKHQRSA-O 0.000 description 1
- 102000001764 CREB-Binding Protein Human genes 0.000 description 1
- 108010040163 CREB-Binding Protein Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 101001028732 Chironex fleckeri Toxin CfTX-A Proteins 0.000 description 1
- 206010008748 Chorea Diseases 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 101100536354 Drosophila melanogaster tant gene Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000289695 Eutheria Species 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 241000714165 Feline leukemia virus Species 0.000 description 1
- 241000714174 Feline sarcoma virus Species 0.000 description 1
- 244000228957 Ferula foetida Species 0.000 description 1
- 241000710831 Flavivirus Species 0.000 description 1
- 208000000666 Fowlpox Diseases 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 241000713813 Gibbon ape leukemia virus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000941423 Grom virus Species 0.000 description 1
- 241001272567 Hominoidea Species 0.000 description 1
- 101000855516 Homo sapiens Cyclic AMP-responsive element-binding protein 1 Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical group C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000288903 Lemuridae Species 0.000 description 1
- 201000000251 Locked-in syndrome Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000713821 Mason-Pfizer monkey virus Species 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 241000289419 Metatheria Species 0.000 description 1
- 241000237852 Mollusca Species 0.000 description 1
- 241000713862 Moloney murine sarcoma virus Species 0.000 description 1
- 241000289390 Monotremata Species 0.000 description 1
- 241000713333 Mouse mammary tumor virus Species 0.000 description 1
- 241000714177 Murine leukemia virus Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 1
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 1
- PBUWKCRTSMWDRY-UHFFFAOYSA-N NC(N)=O.C1=CNC2=C3C=NN=C3C=CC2=C1 Chemical class NC(N)=O.C1=CNC2=C3C=NN=C3C=CC2=C1 PBUWKCRTSMWDRY-UHFFFAOYSA-N 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 241000714209 Norwalk virus Species 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 102000003840 Opioid Receptors Human genes 0.000 description 1
- 108090000137 Opioid Receptors Proteins 0.000 description 1
- 241000702244 Orthoreovirus Species 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 102000002508 Peptide Elongation Factors Human genes 0.000 description 1
- 108010068204 Peptide Elongation Factors Proteins 0.000 description 1
- BHHGXPLMPWCGHP-UHFFFAOYSA-N Phenethylamine Chemical class NCCC1=CC=CC=C1 BHHGXPLMPWCGHP-UHFFFAOYSA-N 0.000 description 1
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- 241000711798 Rabies lyssavirus Species 0.000 description 1
- 241000712907 Retroviridae Species 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000714474 Rous sarcoma virus Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 241000713311 Simian immunodeficiency virus Species 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 241000713675 Spumavirus Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 208000000389 T-cell leukemia Diseases 0.000 description 1
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 1
- 102100035115 Testin Human genes 0.000 description 1
- 101710070533 Testin Proteins 0.000 description 1
- HATRDXDCPOXQJX-UHFFFAOYSA-N Thapsigargin Natural products CCCCCCCC(=O)OC1C(OC(O)C(=C/C)C)C(=C2C3OC(=O)C(C)(O)C3(O)C(CC(C)(OC(=O)C)C12)OC(=O)CCC)C HATRDXDCPOXQJX-UHFFFAOYSA-N 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 241000711975 Vesicular stomatitis virus Species 0.000 description 1
- 206010047571 Visual impairment Diseases 0.000 description 1
- 241000714205 Woolly monkey sarcoma virus Species 0.000 description 1
- LRFVTYWOQMYALW-UHFFFAOYSA-N Xanthine Natural products O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 125000003302 alkenyloxy group Chemical group 0.000 description 1
- 125000005133 alkynyloxy group Chemical group 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 230000024131 anesthesia-resistant memory Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 201000007201 aphasia Diseases 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000035045 associative learning Effects 0.000 description 1
- 208000004668 avian leukosis Diseases 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 230000008238 biochemical pathway Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229930003827 cannabinoid Natural products 0.000 description 1
- 239000003557 cannabinoid Substances 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 208000012601 choreatic disease Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000006690 co-activation Effects 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 230000007278 cognition impairment Effects 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 101150056237 creB gene Proteins 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000012912 drug discovery process Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000000550 effect on aging Effects 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000001339 gustatory effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 229920000140 heteropolymer Polymers 0.000 description 1
- 102000051865 human CREB1 Human genes 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 125000004531 indol-5-yl group Chemical group [H]N1C([H])=C([H])C2=C([H])C(*)=C([H])C([H])=C12 0.000 description 1
- 150000005624 indolones Chemical class 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 201000003723 learning disability Diseases 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000003137 locomotive effect Effects 0.000 description 1
- 230000027928 long-term synaptic potentiation Effects 0.000 description 1
- 231100000863 loss of memory Toxicity 0.000 description 1
- 210000005171 mammalian brain Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000006386 memory function Effects 0.000 description 1
- 229960001252 methamphetamine Drugs 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 230000001343 mnemonic effect Effects 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 238000007479 molecular analysis Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 210000002161 motor neuron Anatomy 0.000 description 1
- 210000001577 neostriatum Anatomy 0.000 description 1
- 210000001178 neural stem cell Anatomy 0.000 description 1
- 210000002241 neurite Anatomy 0.000 description 1
- 230000004031 neuronal differentiation Effects 0.000 description 1
- 230000007171 neuropathology Effects 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 230000003557 neuropsychological effect Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000003957 neurotransmitter release Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 230000017025 olfactory learning Effects 0.000 description 1
- 230000017448 oviposition Effects 0.000 description 1
- 125000004043 oxo group Chemical group O=* 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000008180 pharmaceutical surfactant Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- IWELDVXSEVIIGI-UHFFFAOYSA-N piperazin-2-one Chemical class O=C1CNCCN1 IWELDVXSEVIIGI-UHFFFAOYSA-N 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 208000028173 post-traumatic stress disease Diseases 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 210000000977 primary visual cortex Anatomy 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000005067 remediation Methods 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000000979 retarding effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 238000011808 rodent model Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000001044 sensory neuron Anatomy 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 210000004092 somatosensory cortex Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000024188 startle response Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000032312 synaptic target recognition Effects 0.000 description 1
- 238000012956 testing procedure Methods 0.000 description 1
- IXFPJGBNCFXKPI-FSIHEZPISA-N thapsigargin Chemical compound CCCC(=O)O[C@H]1C[C@](C)(OC(C)=O)[C@H]2[C@H](OC(=O)CCCCCCC)[C@@H](OC(=O)C(\C)=C/C)C(C)=C2[C@@H]2OC(=O)[C@@](C)(O)[C@]21O IXFPJGBNCFXKPI-FSIHEZPISA-N 0.000 description 1
- 229930192474 thiophene Chemical group 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 230000009750 upstream signaling Effects 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 210000005172 vertebrate brain Anatomy 0.000 description 1
- 208000029257 vision disease Diseases 0.000 description 1
- 210000000857 visual cortex Anatomy 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B30/00—Methods of screening libraries
- C40B30/06—Methods of screening libraries by measuring effects on living organisms, tissues or cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
Abstract
[0001] The present invention provides methods and systems for identifying,evaluating, and testing various compounds as memory agents and regimens as training protocols related to memory enhancement and/or impairment. Such methods and systems may test any compounds or protocols, including the memory agents and training protocols described herein. The methods can comprise combining training protocols with the general administration of memory agents. In some embodiments, the present invention may involve identifying, selecting, testing, evaluating or assessing a compound as a drug candidate for a memory agent, for example, as one effective for enhancing or impairing memory. Figure 1
Description
Methods and Systems for Evaluating
Memory Agents
This application claims priority under 35 U.S.C. § 119 to U.S. Provisional Patent
Application Serial No. 61/081,845, filed July 18, 2008, the entire content of which is fully incorporated by reference herein.
The invention relates to methods and systems of evaluating, identifying or assessing the effectiveness of memory agent and/or training protocols administered to subjects.
Memory is the recollection of past experiences. One is able to register new information, store it and then recall it sometime later. Recollection of facts and events represents a form of conscious, or explicit, memory. One also remembers less conscious skills, such as riding a bike, playing a musical instrument or associating simple cues with reward or punishment, which represent more implicit forms of memory. For both of these cases, the process of memory formation appears to proceed through three general stages. Acquisition (learning) involves the initial perception of a new experience. Short-term memory of this newly acquired experience then appears transient and labile. Under appropriate conditions, often requiring repetition and rest, short-term memory of an experience then can be "consolidated" into a more durable long- term memory.
An every-day example of this memory process involves using a phone number. When one first looks up a new phone number, they recite it to themselves a few times to learn it (learning). One then can dial the number successfully within seconds to minutes, if not distracted. Interruptions, on the other hand, almost always cause one to forget the number.
Minutes to hours after dialing the number, one most likely would not remember the number anymore (short-term memory). If the phone number corresponds to that of a friend's new cell phone, however, one might find themselves dialing it repeatedly every day or so. With enough repetition, one eventually can recall the phone number through long-term memory.
The human brain is evolutionarily designed to sense its internal and external environment, to perceive causal relations among stimuli and to change its response adaptively.
To accomplish this incredible task, a self-regulating network of 40 thousand genes directs the development of a cellular network of one hundred billion neurons with 100 trillion connections among them. Such complexity is staggering. Yet neurobiologists have begun to understand how the human brain works in part by studying brain function in other animals.
New experiences obviously can be quite complex, but when reduced in the laboratory to simple, controllable studies of "associations" between two identified stimuli (Pavlovian learning, for instance), the process of memory formation can be studied in many different animals ranging from insects to mammals. These animal studies have contributed to our current understanding of how memory formation proceeds, revealing aspects of neuroanatomy and biochemistry of the brain. Remarkably, these studies have established that much of the basic biochemistry and behavioral phenomenology of memory formation has been evolutionarily conserved throughout the animal kingdom, even though neuroanatomy differs appreciably among species.
These animal studies have shown that memory formation generally proceeds through several functionally distinct temporal phases. Acquisition (LRN) usually requires repetition and is thought to recruit maximal participation of the underlying neural circuitry that normally registers such an experience. Once learning occurs, early memory tends to decay rapidly and is sensitive to disruption by distraction and anesthesia (i.e., anesthesia-sensitive memory; ASM).
Genetic dissection of ASM in {fruit flies has shown that ASM can be further decomposed into short-term memory (STM) and intermediate-term memory (ITM).
By contrast, long-lasting memory becomes resistant to disruption (i.e., anesthesia- resistant memory; ARM) and persists for long periods. Importantly, these animal studies generally have revealed that protein synthesis is required for the appearance of long-term memory (LTM). Once again, fruit fly studies have revealed that (i) LTM, but not ARM, requires protein synthesis and (ii) ARM and L.TM can be genetically dissected into functionally independent phases of memory.
Animal studies also have revealed that the basic wiring diagram of the brain emerges during development. Most connections (synapses) among neurons, however, are crude and non- functional. Subsequent experience is required to refine these synaptic connections, thereby fine tuning the functions of various circuits. A ctivity-dependent synaptic reorganization continues within the adult brain, as well. Learning a new experience initiates a neural activity, which ultimately produces synaptic reorganization among neurons in the relevant circuit. These synaptic changes (synaptic plasticity), distributed throughout the neural circuit, are considered to be the physical basis of long-term memory.
Experience-dependent changes in neural activity initiate within neurons a complex biochemical response. The ultimate effects of this biochemistry are to produce short-term (transient) and long-term (long-lasting) synaptic plasticity. Basic research continues to identify more and more of the signaling pathways and other cell biology that underlie this synaptic plasticity. The first of these to be discovered was the cAMP pathway, a cascade of enzymatic reactions that transduces extracellular neurotransmitter release into intracellular changes in the functional states of many proteins. Neurotransmitters, their corresponding receptors, and cytoplasmic PKA appear to regulate short-term plasticity, while activation of the transcription factor CREB (cAMP response element binding protein) is required to produce long-term plasticity.
In all species studied so far, the CREB gene is expressed in two opposing forms -- an activator or a repressor of downstream, CRE-mediated gene transcription. Key behavioral experiments in Drosophila originally established a critical role for CREB in the formation of long-term memory. Normal fruit flies are capable of learning the association between a particular smell and the punishment of foot shock. After one training session, a majority of flies will avoid the previously shock-paired odor when given a choice between it and a neutral odor in a T-maze. Though such learning initially is quite robust, memory thereafter is transient, decaying away within a day. In contrast, a bona fide protein synthesis-dependent LTM lasting more than a week can be produced in normal flies when subjected to ten training sessions with a 15-min rest interval between them. In flies genetically engineered to produce high levels of
CREB repressor, LTM specifically is blocked with no effects on learning or early memory. In flies genetically engineered to produce high levels of CREB activator, LTM after spaced training is not affected but, surprisingly, is induced after just one training session. In short,
overexpression of CREB activator enhances memory by reducing the number of training sessions required to induce the formation of LTM -- the functional equivalent of a photographic memory.
Molecular studies in several animal models have begun to elucidate further the biochemistry of plasticity and to link various aspects of synaptic plasticity with memory formation, leading to the following general view of brain plasticity: a new experience is registered in a specific neural circuit as a change in neural activity. This neural activity induces a complex inter- and intra- cellular biochemical response that still is being discovered. To date, however, a few key aspects of the process appear evolutionarily conserved. Stimulation of the NMDA receptor appears central to induction of both the local, transient biochemical response at the synapse and the long- lasting biochemical response in the cell nucleus (phosphorylation of CREB). Several intracellular signaling pathways appear to be induced initially by neural activity, but CREB nonetheless appears to be a dominant "downstream" target, regulating the conversion of early memory to lasting memory. Down-regulation of CREB suppresses, while up-regulation of
CREB enhances, a gene transcriptional response underlying a synaptic grow process that yields lasting functional and structural plasticity at synapses. In essence, CREB appears to act as a master switch that determines when neural activity will give rise to lasting, structural changes in a circuit. A key factor influencing this switch is repetition; when the CREB pathway is up- regulated, the number of training sessions required for the formation of long-term memory is decreased.
Four basic objectives guided the approach to screen for drugs that modulated the "CREB pathway." First, for efficiency, the screen had to be high throughput, amenable to robotic manipulations in a 96-well plate format. Second, because any identified drug was ultimately to be used in humans, the preferable target was an endogenous (neuronal) form of human CREB.
Third, when designing the screen, all the relevant upstream signaling pathways that might impinge on CREB function during memory formation were not yet known. Therefore, a broad- based screen, monitoring CREB-dependent gene expression as a functional readout of the CREB pathway seemed more inclusive of any missing, yet potentially important, biochemical signaling.
Finally, the screen needed to identify drugs that had no effect on CREB function alone but rather synergized with co-activation of cAMP signaling. This requirement was designed to mimic the original behavioral experiments. In flies, overexpression of CREB alone had no effect on fly behavior. Rather, training per se was required to produce enhanced memory, because experience-induced increases in neural activity activated the cAMP pathway.
These considerations were incorporated into a high throughput screen (HTS) of cultured human neuroblastoma cells, which were stably transfected with a CRE-luciferase reporter gene.
In this manner, changes in CREB-dependent transcription of luciferase could be monitored via fluorescence. To mimic (at the biochemical level) the associative requirement for memory formation, drugs were sought that produced no change in luciferase activity on their own but synergized (> 2-fold) with a suboptimal dose of forskolin, which activates the cAMP pathway (as does neural activity in vivo). Using a robotic system to screen these cells in 96-well plates, large libraries of drug compounds have been screened efficiently, yielding numerous "active hits." To confirm, these active hits then were assessed at four different concentrations with or without forskolin. Several Confirmed Actives emerged from this screening process.
Interestingly, an efficacious molecular target was discovered to be phosphodiesterase-4 (PDE4). Generally and specifically, this discovery makes sense. Most biochemical pathways function within a well-regulated optimum, with some molecular components accelerating (positive regulators), and others retarding (negative regulators), signal propagation. Given the opposing functions of CREB activator and repressor isoforms, this notion applies to regulation of the CREB switch during long-term memory formation. Like genetic mutations, most drug compounds actually serve as inhibitors of target function ("antagonists" for drugs and "hypomorphs" for mutations). Hence, discovering drug compounds that antagonize negative regulators of a pathway might be expected often from a screen for enhanced function. This, of course, is the case for a PDE inhibitor; decreasing PDE activity leads to an increase of cAMP normally synthesized by adenylyl cyclase (AC), and elevated cAMP leads to activation of CREB via PKA. Moreover, a PDE inhibitor might be expected to have minimal effect alone, in the absence of forskolin-induced activation of AC (or neural activity-induced activation of AC in vivo).
An advanced PDE-4 inhibitor, HT-0712, has been shown to be a validated compound for clinical development, along with several other CREB pathway enhancers in addition to HT-0712.
To date, behavioral assessments in rodent models of memory formation and biochemical experiments have shown that these compounds effectively enhance memory.
It is important to develop, identify and evaluate such compounds and therapies. Such therapies may include particular training protocols and/or administration of such compound or compounds, including compounds that serve as memory agents, which may be memory enhancers that specifically up-regulate the CREB pathway, as well as memory impairers.
The present invention includes methods including the steps of assessing the effectiveness of a memory agent administered to a subject, wherein said assessing comprises presenting to the subject sets of stimuli and evaluating the subject’s response to the stimuli. The assessing may include a first period comprising presenting to the subject stimuli associated into sets and evaluating the subject’s response to the stimuli to establish a criterion; and a second period comprising presenting to the subject stimuli associated into sets and evaluating the subject’s response to the stimuli to establish a long term success measurement.
In some embodiments, the second period begins at least about one day after the completion of the first period.
The evaluating of the subject’s response may include comparing the criterion to the long term success measurement.
The sets of stimuli may include a plurality of pairs of stimuli.
In some embodiments, the each of the plurality of pairs of stimuli can include a positive element and/or a negative element.
In other embodiments, each of the plurality of pairs of stimuli may include an element that has an identifiable association with the other element of the pair.
In some embodiments, this identifiable association may be a face — name association or word — word association.
The subject may be an animal.
In certain embodiments, the animal may be a primate, a mammal, a mouse or a rat.
In some embodiments, the primate may be a human, a monkey, a lemur, a macaque or an ape.
In some embodiments, the first period may be from about one to about ten days.
In some embodiments, the second period may be about one day.
In some embodiments, there may be a plurality of subjects, which may include a control group and an experimental group.
In certain embodiments, the assessing may include comparing the control group to the experimental group.
In some embodiments, the evaluating of the subject’s response includes calculating and/or measuring one or more aspects selected from the group consisting of: the ratio of the long term success measurement to the criterion, long term memory retention, the amount of time required to achieve a particular criterion, and/or the amount of time between the first period and the second period while keeping a constant, near-constant, or improved ratio of the long term success measurement to the criterion.
In other embodiments, the present invention may involve a method including selecting a memory agent as a drug candidate, wherein said selecting includes the steps of: administering a memory agent to a subject; and presenting to the subject sets of stimuli and evaluating the subject’s response to the stimuli. The assessing may further include: a first period comprising presenting to the subject stimuli associated into sets and evaluating the subject’s response to the stimuli to establish a criterion; and a second period comprising presenting to the subject stimuli associated into sets and evaluating the subject’s response to the stimuli to establish a long term success measurement. In some embodiments, the second period begins at least about one day after the completion of the first period. In certain embodiments, the evaluating of the subject’s response comprises calculating and/or measuring one or more aspects selected from the group consisting of: the ratio of the long term success measurement to the criterion, long term memory retention, the amount of time required to achieve a particular criterion, and/or the amount of time between the first period and the second period while keeping a constant, near-constant, or improved ratio of the long term success measurement to the criterion. In some embodiments, the sets of stimuli comprise a plurality of pairs of stimuli. In some embodiments, the subject may be an animal, including an mammal such as a primate, a mouse and a rat.
In yet other embodiments, the present invention involves a method including: testing a memory agent as a long term memory enhancer, wherein said testing includes the steps of: administering a memory agent to a subject; and presenting to the subject sets of stimuli and evaluating the subject’s response to the stimuli. In certain embodiments, the assessing further includes: a first period comprising presenting to the subject stimuli associated into sets and evaluating the subject’s response to the stimuli to establish a criterion; and a second period comprising presenting to the subject stimuli associated into sets and evaluating the subject’s response to the stimuli to establish a long term success measurement. In some embodiments, the second period begins at least about one day after the completion of the first period. In some embodiments, the evaluating of the subject’s response comprises calculating and/or measuring one or more aspects selected from the group consisting of: the ratio of the long term success measurement to the criterion, long term memory retention, the amount of time required to achieve a particular criterion, and/or the amount of time between the first period and the second period while keeping a constant, near-constant, or improved ratio of the long term success measurement to the criterion. In certain embodiments, the sets of stimuli comprise a plurality of pairs of stimuli. In some embodiments, the subject may be an animal, including an animal selected from the group consisting of a primate, a mammal, a mouse and a rat.
In yet further embodiments, the present invention may be a method including: assessing the effectiveness of a memory agent, wherein said assessing comprises the steps of: providing a first subject and a second subject, wherein the first subject and the second subject are of the same species; administering a memory agent to the first subject; presenting the first subject and the second subject a plurality of pairs of stimuli during a first period and evaluating the first subject and the second subject’s responses to the stimuli to establish a criterion for each of the first subject and the second subject; presenting the first subject and the second subject the plurality of pairs of stimuli during a second period and evaluating the first subject and the second subject’s responses to the stimuli to establish a long term success measurement for each of the first subject and the second subject; comparing the first subject and the second subject’s criterions to their respective long term success measurements. In some embodiments, the second period begins at least about one day after the completion of the first period. In some embodiments, the second period begins from about 1 to about 10 days following the completion of the first period. In certain embodiments, the comparing of the criterions to the long term success measurements comprises: establishing a first ratio of the first subject’s long term success measurement to the first subject’s criterion; establishing a second ratio of the second subject’s long term success measurement to the second subject’s criterion; and comparing the first ratio to the second ratio.
In certain embodiments, the sets of stimuli include a plurality of pairs of stimuli. In some embodiments, the plurality of pairs of stimuli comprises a positive element and/or a negative element. In other embodiments, each of the plurality of pairs of stimuli comprises an element that has an identifiable association with the other element. In some embodiments, the identifiable association is selected from the group consisting of a face — name association and a word — word association. In some embodiments, each of the first subject and the second subject is an animal, including an animal is selected from the group consisting of a primate (including a human, a monkey, a lemur, a macaque and an ape), a mammal, a mouse and a rat. In certain embodiments, the first period comprises from about one to about ten days. In some embodiments, the second period comprises about one day. In some embodiments, each of the first subject and the second subject is a plurality of subjects.
In some embodiments, the present invention includes methods similar to those recited above, but which focus on evaluating an training protocol rather than or in addition to a memory agent. Some embodiments involve a method including the steps of: assessing the effectiveness of an training protocol administered to a subject, wherein said assessing comprises presenting to the subject sets of stimuli and evaluating the subject’s response to the stimuli. Other embodiments involve a method including: testing a training protocol as a long term memory enhancer, wherein said testing includes the steps of: administering an training protocol to a subject; and presenting to the subject sets of stimuli and evaluating the subject’s response to the stimuli. Further embodiments involve a method including: assessing the effectiveness of an training protocol, wherein said assessing includes the steps of: providing a first subject and a second subject, wherein the first subject and the second subject are of the same species; administering an training protocol to the first subject; presenting the first subject and the second subject a plurality of pairs of stimuli during a first period and evaluating their responses to the stimuli to establish a criterion for each of the first subject and the second subject; presenting the first subject and the second subject the plurality of pairs of stimuli during a second period and evaluating their responses to the stimuli to establish a long term success measurement for each of the first subject and the second subject; comparing the criterions of the first subject and the second subject to their respective long term success measurements.
The present invention also includes systems, including systems for use along with the methods disclosed herein. For example, in some embodiments, the system may include all elements necessary to perform an embodiment of the methods of the present invention. Systems of the present invention may be useful for selecting a memory agent as a drug candidate, assessing the effectiveness of a memory agent, assessing the effectiveness of a training protocol, and/or testing a memory agent as a long term memory enhancer, and/or testing a memory agent along with an training protocol as a long term memory enhancer.
In some embodiments, a system of the present invention includes sets of stimuli, wherein said sets of stimuli are configured to permit evaluation of a subject’s response to the sets of stimuli and thereby assess the effectiveness of an training protocol administered to the subject.
In some embodiments, the sets of stimuli comprise a plurality of pairs of stimuli. In certain embodiments, each of the plurality of pairs of stimuli comprises a positive element and/or a negative element. In some embodiments, each of the plurality of pairs of stimuli comprises an element that has an identifiable association with the other element of the pair. In further embodiments, the identifiable association is selected from the group consisting of a face — name association and a word — word association. In other embodiments, the system may further include testing protocols, testing schedules, and/or memory agent dosage and administration schedules.
In other embodiments a system of the present invention includes sets of stimuli, wherein said sets of stimuli are configured to permit evaluation of a subject’s response to the sets of stimuli and thereby assess the effectiveness of a memory agent administered to the subject. In some embodiments, the sets of stimuli comprise a plurality of pairs of stimuli. In various embodiments, each of the plurality of pairs of stimuli comprises a positive element and/or a negative element. In other embodiments, each of the plurality of pairs of stimuli comprises an element that has an identifiable association with the other element of the pair. In certain embodiments, the identifiable association is selected from the group consisting of a face — name association and a word — word association. In other embodiments, the system may further include testing protocols, testing schedules, and/or memory agent dosage and administration schedules.
In some embodiments, the methods and systems of the present invention utilize a memory agent that is one or more selected from the group consisting of a compound having the structure: . 3
Fy ®
KS 1 i ° Fe Fie [1 we ~Y ¥y
EY wherein each of Yi, Y2, Y3, and Y4 is independently --H; straight chained or branched C;-
C7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C,-C; alkenyl or alkynyl; Cs-C7 cycloalkyl or Cs-C7 cycloalkenyl; --F, --Cl1, --Br, or --1; --NO»; --N3; --CN; --ORy, --SRy, --OCORy, --CORy, --NCORy, --N(Ry)2, --CON(Ry),, or --COORy; aryl or heteroaryl; or any two of Yy, Y,, Y3 and Y, present on adjacent carbon atoms can constitute a methylenedioxy group; wherein each Ry is independently --H; straight chained or branched C;-C7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C,-C7 alkenyl or alkynyl; Cs-
C7 cycloalkyl, Cs-C7 cycloalkenyl, aryl or aryl(C;-Cs)alkyl; wherein A is A’, straight chained or branched C;-C5 alkyl, aryl, heteroaryl, aryl(C;-Cg)alkyl or heteroaryl(C;-Cg)alkyl; wherein A' is
Tn % “\_Y i,
NN. Pow lm ee SEE, wherein R; and R; are each independently H, straight chained or branched C;-C7 alkyl, -
F, --Cl, --Br, --1, --NO,, or --CN; wherein Rj is H, straight chained or branched C;-C7 alkyl, --F, --Cl, --Br, --1, --NO3, --CN, --OReg, aryl or heteroaryl; wherein Rs is straight chained or branched C;-Cy alkyl, --N(Ry),, --ORy4 or aryl; wherein Rg is straight chained or branched C;-C7 alkyl or aryl; wherein B is aryl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, indolizinyl, indol-
4-yl, indo1-5-yl, indol-6-yl, indol-7-yl, isoindolyl, benzo[b]furan-4-yl, benzo[b]furan-5-yl, benzo[b]furan-6-yl, benzo[b]furan-7-yl, benzo[b]thiophen-4-yl, benzo[b]thiophen-5-yl, benzo[b]thiophen-6-yl, benzo[b]thiophen-7-yl, indazolyl, benzimidazolyl, benzo[b]thiazolyl, purinyl, imidazo[2,1-b]thiazolyl, quinolinyl, isoquinolinyl, quinazolinyl, 2,1,3-benzothiazolyl, furanyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, triazolyl, thiadiazolyl, benzoxazolyl, benzisoxazolyl, cinnolinyl, quinoxalinyl, 1,8- napthyridinyl, pteridinyl, or phthalimidyl; provided however, that the carbon atom or carbon atoms ortho to the nitrogen atom of the imine bond may only be substituted with one or more of the following --F, -Cl, --Br, --1, --CN, methyl, ethyl or methoxy; wherein n is an integer from 1 to 4 inclusive; wherein aryl is phenyl or napthyl, including phenyl and napthyl substituted with one or more of the following: -F, -Cl, -Br, -I, -NO,, -CN, straight chained or branched C;-C7 alkyl, straight chained or branched C;-C7; monofluoroalkyl, straight chained or branched C;-C polyfluoroalkyl, straight chained or branched C,-C7 alkenyl, straight chained or branched C,-C7 alkynyl, Cs-C; cycloalkyl, C;-C7 monofluorocycloalkyl, Cs-C7 polyfluorocycloalkyl, Cs-Cy cycloalkenyl, -ORy4, SRy, -OCORy, -CORy, -NCORy, -CO;Ry, -CON(Ry); or (CH,),-O- (CH;)mCHs; or a pharmaceutically acceptable salt thereof
In some embodiments, the methods and systems of the present invention utilize a memory agent that is one or more selected from the group consisting of a compound having the structure:
CF,
CF,
N
/ N
CC
OH or
O
® NH
CH;
OcPent
OMe wherein Me is methyl, cPent is cyclopentyl and the 3 and 5 carbons are in the S configuration.
FIGS. 1A — 1B illustrate graphs showing results from an embodiment of the present invention described in Example 1. Results are expressed as mean days + s.e.m per treatment, * p < 0.05 versus vehicle.
FIGS. 2A - 2B illustrate graphs showing results from an embodiment of the present invention described in Example 1. Results are expressed as mean percent performance + s.e.m. per treatment.
FIGS. 3A — 3B illustrate graphs showing results from an embodiment of the present invention described in Example 1. Results are expressed as mean percent performance + s.e.m. per treatment.
FIGS. 4A - 4D illustrate exemplary pairs of visual stimuli that may be used in an embodiment of the present invention described in Example 1.
FIG. 5 illustrates a graph showing performance of healthy elderly volunteers in a paired- associate (face-name) memory assay embodiment described in Example 2. Subjects were asked to memorize a set of 40 pairs of faces and names (professions) for 6 days (d2 — d7). On training days, subjects went through the list of 40 pairs only once. They were queried for their recall first and then given the correct answers to continue training. After training, three-day memory retention was quantified using only face-name pairs 1 — 20 (d10). Seven-day memory retention was quantified again for these face-name pairs 1 — 20 (d14b). Seven-day retention also was quantified for face-name pairs 21 — 40 twice (d14a and d14a2), with a 1-min interval between recall sessions.
In the following paragraphs, the present invention will be described by way of example with reference to the attached figures. Throughout this description, the preferred embodiments and examples shown should be considered as exemplars, rather than as limitations on the present invention. As used herein, the “present invention” refers to any one of the embodiments of the invention described herein, and any equivalents. Furthermore, reference to various feature(s) of the “present invention” throughout this document does not mean that all claimed embodiments or methods must include the referenced feature(s).
The terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention. As used herein and in the appended claims, the singular forms “a,” “an,” and “the” include the plural reference unless the context clearly dictates otherwise. Thus, for example, a reference to “a compound” is a reference to one or more compounds and includes equivalents thereof known to those of ordinary skill in the art and so forth.
Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art to which this invention belongs. Specific methods, devices, and materials are described, although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention.
The present invention provides methods and systems for identifying, evaluating, and testing various compounds as memory agents and regimens as training protocols. Such methods and systems may test any compounds or protocols, including the memory agents and training protocols described herein. The methods can comprise combining training protocols with the general administration of memory agents. In some embodiments, the present invention may involve identifying, selecting, testing, evaluating or assessing a compound as a drug candidate for a memory agent, for example, as one effective for enhancing memory.
A drug candidate may be a compound that has been identified through a drug discovery process and has been synthesized, characterized, optimized, and/or screened or assayed. Once a compound has been shown to have potential for a given activity or effect, for example by use of the methods or systems of the present invention, it may be a drug candidate — i.e., one that may be put through clinical trials with the intent that it be ultimately commercialized.
METHODS OF IDENTIFYING, EVALUATING AND TESTING MEMORY
AGENTS AND TRAINING PROTOCOLS
In some embodiments, the present invention involves the use of certain tasks to assess one or more aspects of an animal’s memory capabilities. For example, the animal’s learning capabilities, short term memory, or long term memory retention may be tested and/or evaluated.
As used herein, the term "memory," without an additional modifier (e.g., short term memory), refers to long term memory. As used herein, the term "memory agent" refers to memory augmenting agents or memory suppressing agents. Memory augmenting and suppressing agents include, but are not limited to, those molecules, compounds, and/or agents that act on a CREB pathway, as described, for example, in U.S. Patent Nos. 5,929,223, 6,051,559, 6,689,557, and 6,890,516, and in U.S. Patent Application Serial No. 11/066,125, the disclosure of each of which is incorporated by reference in their entirety herein.
As used herein, the term “animal” includes mammals, as well as other animals, vertebrate, invertebrate (e.g., birds, fish, reptiles, insects (e.g., Drosophila species) and mollusks
(e.g., Aplysia)). The terms “mammal” and “mammalian”, as used herein, refer to any vertebrate animal, including monotremes, marsupials and placental, that suckle their young and either give birth to living young (eutharian or placental mammals) or are egg-laying (metatharian or nonplacental mammals). Examples of mammalian species include, without limitation, humans and primates (e.g., monkeys, chimpanzees, humans, apes, lemurs, or macaques), rodents (e.g., rats, mice, guinea pigs) and ruminents (e.g., cows, pigs, horses).
The animal can be an animal with some form and degree of memory dysfunction or an animal with normal memory performance (i.e., an animal without any form of memory failure (dysfunction or loss of any memory)). One or more animals may be used and such animals may be placed in one or more groups (e.g., one or more control groups and/or one or more experimental groups). The animal may be any suitable age.
The tasks may involve the presentation of certain stimuli to the subjects. The stimuli may be any suitable sensory stimulus including, without limitation, auditory, visual, tactile, olfactory, gustatory and/or combinations thereof. In some embodiments, the stimuli may be visual and be one or more of a symbol, letter, number, line, shape, color, picture or combinations thereof. The stimuli may be associated into sets, such that a certain relationship is established between the members of the sets. The stimuli may be associated into groups of about 2, 3,4, 5, 6,7, 8, 9 or 10. In some such embodiments, the stimuli are associated into pairs. In some embodiments, each stimulus in the pair is of the same type (i.e., audio, visual or tactile) while in other embodiments the pair may be of different types. In some embodiments, an element in the pair will have some identifiable association with the other element of the pair. An identifiable association can be a visual, audible, logical or other aspect of the one or more elements of the pair that would cause one to associate that element of the pair with its corresponding element. In other embodiments, there may be no identifiable association. For example, the pair could be a word-word pair wherein one word does not have an identifiable association with the other word (e.g., comb-apple). An example of visual paired stimuli is depicted in FIGs. 4A-4D. Another example of a stimulus pair with an identifiable association could be a face — name pairing and/or an occupation — face/name pairing. In some embodiments, there may also be an occupation listed along with the face — name pairing.
In some embodiments, the subjects may be presented one or more pairs of stimuli. In some embodiments, 2, 3,4,5,6,7,8,9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 50, 100, 120, 150, or any other suitable number of pairs of stimuli may be presented to the subject. In some embodiments, one element of the pair is designated to be positive — meaning that the subject will receive a reward if it selects that element. In other embodiments, one element of the pair is designated to be negative — meaning that the subject will receive negative feedback if it selects that element. In some embodiments, the subject selects the element by touching the element, but in other embodiments any other suitable selection method may be used. In some embodiments, the reward may be food, but in other embodiments the reward may be a pleasant sound, access to certain toys or items, or anything suitable for triggering a positive response from the subject. In some embodiments, the negative feedback is a shock, a sound, a punishment or withholding of privileges, or any suitable action or the like that provides the subject with negative feedback.
The type of feedback, the selection of the pairs of stimuli, sets of pairs of stimuli, species and age of the subjects, and other aspects of the tasks may be modified to test and/or evaluate different aspects of a subject’s memory. For example, using stimulus pairs wherein each element has an identifiable association to the other element may be used to evaluate the subject’s relational memory.
In other embodiments, other evaluation methods other than the reward and/or negative feedback evaluation methods may be used. For example, in some embodiments, such as those where the subject is human, the stimuli may have a relation such that the subject may determine if the pairing or other association is correct or incorrect (e.g., are the stimuli paired such that the intended identifiable association between one element of a pair and the other element in the pair is present). For example, if a face — name pairing has been taught to the subject, the subject may be presented pairs of stimuli that have been scrambled such that the correct face — name pairing has been disrupted. The subject could then communicate whether the face — name pairing presented to it is the correct face — name pairing it has been taught. In such embodiments, no discrete reward would be necessary, or the reward could simply be feedback on the correctness of the human’s responses. The pairs of stimuli may be presented in any suitable fashion. For example, the pairs may be presented in random, organized, or a pseudo-random order during each testing session.
The subjects may be tested over any suitable period at any suitable frequency. For example, the subjects may be tested 1, 2, 3, 4,5,6,7,8,9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 50, 60, 75, 100, 150, 200, 250, 365, or any other suitable number of times per testing event (e.g., if testing is daily, the subject may be tested once, twice, three times, etc).
In such testing, subjects may be shown any suitable number of stimuli or pairs of stimuli.
Subjects may have tests daily, every other day, weekly, bi-weekly, monthly, or any other suitable frequency. Moreover any suitable number of subjects may be tested. In some embodiments, testing is done in an effort to teach or encode the subject with the information as to the relationship between the paired stimuli. For example, the testing may be done to teach the subject which of the elements of the pair is the positive and/or negative element. In other embodiments, the testing may be done to teach the subject the correct pairing of elements within a set of stimuli (e.g., the correct face — name, occupation-name, or occupation-face/name association). In such embodiments, a plurality of phases of testing would likely be required. A first teaching phase, followed by a second phase wherein the subject’s knowledge is tested by asking, through an appropriate method depending on the subject type (e.g., human vs. rat), if the presented pairings are correct.
The subjects may be evaluated in any suitable manner. In some embodiments, the subjects are presented with one or more pairs of stimuli in which one element of the pair is designated positive and/or one element of the pair is designated negative. In such an embodiment, the subject, having learned which element of the pair is the positive and/or negative element, is evaluated on the number of times it selects the positive and/or negative element and/or does not select the positive and/or negative element. In other embodiments, the pairs of stimuli may have a relation to one another (e.g., a face — name relation, occupation-name relation, occupation-face/name relation, a pair of words, a set of letters or numbers, parts of a picture or symbol). In such embodiments, the subject may be evaluated on its ability, having learned the correct relation between the elements of the pair, to re-establish the appropriate pairs (e.g., placing the name element with the corresponding picture element, or the like). In some embodiments, the pairs may be altered in some manner and the subject could be asked to identify the manner in which the pair was altered (for example, the response could be “intact,” “rearranged,” “one new,” or “both new”).
In some embodiments, a subject’s long-term memory may be tested. In such embodiments, a criterion result can be established. Such a criterion may be established in a variety of manners. For example, in embodiments where a pair of stimuli is presented to the subject wherein one element of the pair is positive and/or one element of the pair is negative, the subject may be presented with the pair (or sets of pairs) until the subject identifies the positive and/or negative element with a certain frequency. That frequency would then serve as a criterion against which later results may be evaluated. Similarly, the frequency of the correct establishment of the relation between elements of a pair of stimuli may also be used to establish a criterion. In some embodiments, a subject is evaluated until it reaches a certain success rate.
For example, a criterion of about 50%, 55%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, 100%, or any other suitable percentage or number of correct results could be used as a target. In other embodiments, a subject may be tested a certain number of times or over a certain period of time, and the last evaluation may be used to establish the criterion. For example, a period of about 1-23 hours or about 1, 2, 3,4, 5,6, 7, 8,9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23,24, 25,50, 60,75, 100, 150, 200, 250, or 365 days, or any other suitable number of hours or days may be used to establish the criterion. Also, the subject may be tested about 1, 2, 3, 4, 5, 6, 7,8,9,10,11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 50, 60, 75, 100, 150, 200, 250, 365, or any other suitable number of times to establish a criterion. The criterion may also be established using a mean, median, or other statistical measure of the subject’s actual results.
In some embodiments, once the criterion is established, the subject is not evaluated or shown any of the pairs of stimuli used to establish the criterion for a certain amount of time.
This amount of time may be about 1, 2, 3,4, 5,6, 7,8,9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 50, 60, 75, 100, 150, 200, 250, 365, or any other suitable number of days.
After the delay period, the subject is once again tested using the same pairs of stimuli used to establish the criterion. In some embodiments, these tests are repeated under circumstances identical, similar, or different to those used in establishing the criterion. Moreover, the subject’s performance may be evaluated by establishing a long term success measurement in any suitable manner. In some embodiments, the manner of establishing the long term success measurement may be similar to that described with respect to establishing a criterion, albeit using a generally shorter time period such that the long term success measurement is indicative of the subject’s memory, rather than it having relearned the relevant criteria. The subject could then be evaluated by comparing the long term success measurement with the criterion. Statistical or similar analysis may be used to evaluate such results.
In some embodiments, the methods of the present invention may be used to evaluate the efficacy of a potential memory agent and/or a potential training protocol. For example, the methods of the present invention may be used to identify a reduction in the amount of training required to reach a chosen performance level. In such embodiments, a subject may first be evaluated in the absence of a memory agent and subsequently evaluated having been administered a memory agent. Also, a control group of subjects could be tested using certain pairs of stimuli and those results compared to a group of subjects having been administered a given dose of a memory agent. The evaluation of the memory agent and/or training protocol may take a variety of forms. For example, a memory agent may reduce the time and/or number of days of training sessions required to establish or meet a certain criterion, or any other suitable measure of efficacy.
In some embodiments of the present invention, the memory agent is evaluated to see if it alters (e.g., reduces or increases) the number of days or training sessions to reach a criterion of performance. As used herein, the term "criterion" refers to a metric of a desired result and/or a desired level of performance such as, for example, a percentage of correct responses (e.g., correctly paired stimuli) from a test subject or group of test subjects. The criterion may be changed or chosen as desired by the administrator of the protocol, tests, tasks, and/or other embodiments of the present invention. The complexity of the training administered in these embodiments may be manipulated by, for example, changing the criterion, the numbers and/or types stimuli to be paired, the number of days of training, the quantity of training, and/or the type of training. In further embodiments, the training, with or without the memory agent, is sufficient to produce a CREB-dependent change in long term memory, for example a CREB-dependent enhancement of long term memory.
In some embodiments, the methods of the present invention may be used to evaluate the efficacy of a memory impairer. Such embodiments may involve steps similar to or identical to the methods for evaluating a memory agent. However, in such an embodiment, the evaluated indicia would be different. For example, the memory impairer may increase the time required to establish a certain criterion, increase the number of training sessions required to reach a criterion, decrease the ratio of the long term success measurement to the criterion, or any may be evaluated in any other suitable manner.
Any suitable memory agent or memory impairer may be provided by any suitable method, via any suitable delivery system and using any suitable delivery schedule and dose. In addition, any suitable training protocol may be used. Exemplary training protocols, memory agents and memory impairers are specifically discussed in the following sections.
The present invention also includes systems, including systems for use along with the methods disclosed herein. For example, in some embodiments, the system may include all elements necessary to perform an embodiment of the methods of the present invention. Systems of the present invention may be useful for selecting a memory agent as a drug candidate, assessing the effectiveness of a memory agent, assessing the effectiveness of a training protocol, testing a memory agent as a long term memory enhancer, testing a memory agent as a impairer of specific or general memories, and/or testing a memory agent along with a training protocol as a long term memory enhancer. Such systems may involve use of sets of stimuli as described above, including paired stimuli, and testing schedules and protocols as described above.
TRAINING PROTOCOLS
As described herein, assessment using the methods and systems of the present invention can comprise two parts: (1) a specific training protocol and (2) administration of a memory agent. In some embodiments, only the training protocol is used. In other embodiments, both training and administration of a memory agent occur. This combination can augment training protocols by reducing the number of days of training sessions required to yield a performance gain relative to that obtained with training alone or by requiring shorter or no rest intervals between training sessions to yield a performance gain. This combination can also augment training protocols by reducing the duration and/or number of training sessions required for the induction in a specific neuronal circuit(s) of a pattern of neuronal activity or by reducing the duration and/or number of training sessions or underlying pattern of neuronal activity required to induce cyclic AMP response element binding protein (CREB) - dependent long-term structural/function (i.e., long-lasting) change among synaptic connections of the neuronal circuit.
In this manner, one can improve the efficiency of existing training protocols, thereby yielding significant functional and economic benefits.
Training protocols (e.g., massed training, spaced training) are employed in learning a new language or in learning to play a new musical instrument. Administration of a memory agent in conjunction with training reduces the time and/or number of training sessions required to yield a gain in performance. As a result, less practice (training sessions) is required to learn the new language or to learn to play the new musical instrument.
Training protocols are employed for repeated stimulation of neuronal activity or a pattern of neuronal activity underlying (a) specific neuronal circuit(s) in individuals. Administration of a memory agent in conjunction with training reduces the time and/or number of training sessions and/or underlying pattern of neuronal activity required to achieve a given result, such as induction of CREB-dependent long-term structure/function (i.e., long-lasting) change among synaptic connections of the neuronal circuit.
These methods can enhance specific aspects of memory in an animal (particularly a human or other mammal or vertebrate) in need thereof by (a) administering to the animal a memory agent, for example one that enhances CREB pathway function; and (b) training the animal under conditions sufficient to produce an improvement in performance of a memory task of interest by the animal. In some embodiments, the memory agent is a CREB pathway- enhancing drug.
The described methods can be used to treat a memory deficit associated with a central nervous system (CNS) disorder or condition in an animal in need of said treatment by (a) administering to the animal a memory agent, for example one that enhances CREB pathway function; and (b) training the animal under conditions sufficient to produce an improvement in performance of a particular memory task by the animal. CNS disorders and conditions include age-associated memory impairment, neurodegenerative diseases (e.g., Alzheimer’s disease,
Parkinson’s disease, Huntington’s disease (chorea), other senile dementia), psychiatric diseases (e.g., depression, schizophrenia, autism, attention deficit disorder), trauma dependent loss of function (e.g., cerebrovascular diseases (e.g., stroke, ischemia), brain tumor, head or brain injury), genetic defects (e.g., Rubinstein-Taybi syndrome, down syndrome), learning disabilities, and/or combinations thereof.
The described methods can also be used for repeated stimulation of neuronal activity or a pattern of neuronal activity, such as that underlying a specific neuronal circuit(s), in an animal comprising (a) administering to the animal a memory agent, for example one that enhances
CREB pathway function; and (b) training the animal under conditions sufficient to stimulate or induce neuronal activity or a pattern of neuronal activity in the animal.
For many tasks in many species, including human, spaced training protocols (multiple training sessions with a rest interval between each) produce stronger, longer-lasting memory than massed training protocols (multiple training sessions with no rest interval in between).
Behavior-genetic studies of Pavlovian olfactory learning in Drosophila have established that massed training produces a long-lasting memory that nevertheless decays away in at least four days, is not protein synthesis-dependent, is not disrupted by over-expression of a CREB- repressor transgene, and is disrupted in radish mutants (Tully, T. et al., Cell, 79(1):35-47 (1994); and Yin, J. C. et al., Cell, 79(1):49-58 (1994)). In contrast, spaced training produces a long- lasting memory that persists for at least seven days, is protein synthesis-dependent, is disrupted by over-expression of a CREB-repressor transgene and is normal in radish mutants (Tully, T. et al., Cell, 79(1):35-47 (1994); and Yin, J. C. et al., Cell, 79(1):49-58 (1994)). One day after spaced training, memory retention is composed of both the protein synthesis- and CREB- independent early memory (ARM) and the protein synthesis- and CREB-dependent long-term memory (LTM). Additional massed training is insufficient to induce LTM (Tully, T. et al., Cell, 79(1):35-47 (1994); and Yin, J. C. et al., Cell, 79(1):49-58 (1994)).
A growing body of evidence extends these results from invertebrates to mammals. For example, in Aplysia, molecular manipulations of CREB expression, similar to those in flies, suppress or enhance (i) LTM of a facilitatory electrophysiological response at a sensorimotor monosynapse in cell culture and (ii) the synaptic connections between sensory and motor neurons that are normally produced after spaced applications of the facilitatory stimulus (Bartsch, D. et al, Cell, 83(6):979-992 (1995)). In rats, injections of antisense RNA oligonucleotides into hippocampus or amygdala block L'TM formation of two different tasks that are dependent on activity in these anatomical regions, respectively (Guzowski, J. I. et al., Proc.
Natl. Acad. Sci. USA, 94(6):2693-2698 (1997); and Lamprecht, R. et al., J. Neurosci., 1S 17(21):8443-8450 (1997)). In mice, LTM formation for both implicit and explicit tasks is defective in CREB mutant mice (Bourtchuladze, R. et al., Cell, 79(1):59-68 (1994)).
Training of transgenic mice, carrying a CRE-dependent reporter gene (betagalactosidase), in hippocampal-dependent contextual fear conditioning or passive avoidance tasks induces CRE- dependent reporter gene expression in areas CAl and CA3 of the hippocampus. Training of these mice in an amygdala-dependent fear conditioning task induces CRE-dependent reporter gene expression in the amygdala, but not the hippocampus. Thus, training protocols that induce L.TM formation also induce CRE-dependent gene transcription in specific anatomical areas of the mammalian brain (Impey, S. et al., Nat. Neurosci., 1(7):595-601 (1998)).
With these animal models, three salient cases of TM enhancement have been demonstrated. First, over-expression of a CREB-activator transgene abrogates the requirements for multiple, spaced training sessions and, instead, induces .TM formation after only one training session (which normally produces little or no memory retention 24 hours later (Yin, J. C. etal, Cell, 81(1):107-115 (1995)). Second, injection of a virally expressed CREB-activator transgene into rat amygdala also is sufficient to enhance memory after massed training for the fear-potentiated startle response, which abrogates the requirement for a rest interval in spaced training (Josselyn, S. A. et al., Society for Neuroscience, Vol. 24, Abstract 365.10 (1998)).
Third, LTM formation in CREB-deficient mice (Bourtchuladze, R. et al., Cell, 79(1):59-68 (1994)) can form normally, if mutant mice are subjected to a different, spaced training protocol (Kogan, J. H. et al., Curr. Biol., 7(1):1-11 (1997)).
CREB also appears involved in various forms of developmental and cellular plasticity in the vertebrate brain. For example, neuronal activity increases CREB activity in the cortex (Moore, A. N. et al., J. Biol. Chem., 271(24):14214-14220 (1996)). CREB also mediates developmental plasticity in the hippocampus (Murphy, D. D. et al., Proc. Natl. Acad. Sci. USA, 94(4):1482-1487 (1997)), in the somatosensory cortex (Glazewski, S. et al., Cereb. Cortex, 9(3):249-256 (1999)), in the striatum (Liu, F. C. et al., Neuron, 17(6):1133-1144 (1996)), and in the visual cortex (Pham, T. A. et al., Neuron, 22(1):63-72 (1999)).
CREB appears to be affected in human neurodegenerative disease and brain injury. For example, CREB activation and/or expression is disrupted in Alzheimer’s disease (Ikezu, T. et al.,
EMBO J., 15(10):2468-2475 (1996); Sato, N. et al., Biochem. Biophys. Res. Commun. 232(3):637-642 (1997); and Yamamoto-Sasaki, M. et al., Brain. Res., 824(2):300-303 (1999).
CREB activation and/or expression is also elevated after seizures or ischemia (Blendy, J. A. et al., Brain Res., 681(1-2):8-14 (1995); and Tanaka, K. et al., Neuroreport, 10(11):2245-2250 (1999)). “Environmental enrichment” is neuroprotective, preventing cell death by acting through
CREB (Young, D. et al., Nat. Med., 5(4):448-453 (1999)).
CREB functions during drug sensitivity and withdrawal. For example, CREB is affected by ethanol (Pandey, S. C. et al., Alcohol Clin. Exp. Res., 23(9):1425-1434 (1999);
Constantinescu, A. et al., J. Biol. Chem., 274(38):26985-26991 (1999); Yang, X. et al., Alcohol
Clin. Exp. Res., 22(2):382-390 (1998); Yang, X. et al., J. Neurochem., 70(1):224-232 (1998); and Moore, M. S. et al., Cell, 93(6):997-1007 (1998)), by cocaine (Carlezon, W. A., Jr. et al.,
Science, 282(5397):2272-2275 (1998)), by morphine (Widnell, K. L. et al., J. Pharmacol. Exp.
Ther., 276(1):306-315 (1996)), by methamphetamine (Muratake, T. et al., Ann N.Y. Acad. Sci., 844:21-26 (1998)) and by cannabinoid (Calandra, B. et al., Bur. J. Pharmacol., 374(3):445-455 (1999); and Herring, A. C. et al., Biochem. Pharmacol., 55(7):1013-1023 (1998)).
A signal transduction pathway that can stimulate the CREB/CRE transcriptional pathway is the cAMP regulatory system. Consistent with this, mice lacking both adenylate cyclase 1 (AC1) and ACS enzymes fail to learn (Wong S. T. et al., Neuron, 23(4):787-798 (1999)). In these mice, administration of forskolin to area CA1 of the hippocampus restores learning and memory of hippocampal-dependent tasks. Furthermore, treatment of aged rats with drugs that elevate cAMP levels (such as rolipram and D1 receptor agonists) ameliorates an age-dependent loss of hippocampal-dependent memory and cellular long-term potentiation (Barad, M. et al.,
Proc. Natl. Acad. Sci. USA, 95(25):15020-15025 (1998)). These latter data suggest that a cAMP signaling is defective in learning-impaired aged rats (Bach, M. E. et al., Proc. Natl. Acad. Sci.
USA, 96(9):5280-5285 (1999)).
A growing body of evidence suggests that neurons continue to proliferate in the adult brain (Arsenijevic, Y. et al., Exp. Neurol., 170: 48-62 (2001); Vescovi, A. L. et al., Biomed.
Pharmacother., 55:201-205 (2001); Cameron, H. A. and McKay, R. D., J. Comp. Neurol., 435:406-417 (2001); and Geuna, S. et al., Anat. Rec., 265:132-141 (2001)) and that such proliferation is in response to various experiences (Nilsson, M. et al., J. Neurobiol., 39:569-578 (1999); Gould, E. et al., Trends Cogn. Sci., 3:186-192 (1999); Fuchs, E. and Gould, E., Eur. J.
Neurosci., 12: 2211-2214 (2000); Gould, E. et al., Biol. Psychiatry, 48:715-720 (2000); and
Gould, E. et al., Nat. Neurosci., 2:260-265 (1999)). Experimental strategies now are underway to transplant neuronal stem into adult brain for various therapeutic indications (Kurimoto, Y. et al, Neurosci. Lett., 306:57-60 (2001); Singh, G., Neuropathology, 21:110-114 (2001); and
Cameron, H. A. and McKay, R. D., Nat. Neurosci., 2:894-897 (1999)). Much already is known about neurogenesis in embryonic stages of development (Saitoe, M. and Tully, T., “Making connections between synaptic and behavioral plasticity in Drosophila”, In Toward a Theory of
Neuroplasticity, J. McEachern and C. Shaw, Eds. (New York: Psychology Press.), pp. 193-220 (2000)). Neuronal differentiation, neurite extension and initial synaptic target recognition all appear to occur in an activity-independent fashion. Subsequent synaptogenesis and synaptic growth, however, then requires ongoing neuronal activity to fine-tune synaptic connections in a functionally relevant manner. These findings suggest that functional (final) integration of transplanted neural stem cells require neuronal activity. Thus, ACT can be used to exercise appropriate neuronal circuits to fine-tune the synaptic connections of newly acquired, transplanted stem cells that differentiate into neurons. By “exercise appropriate neuronal circuit(s)” is meant the induction in the appropriate neuronal circuit(s) of a pattern of neuronal activity, which corresponds to that produced by a particular cognitive training protocol. The cognitive training protocol can be used to induce such neuronal activity. Alternatively, neuronal activity can be induced by direct electrical stimulation of the neuronal circuitry. “Neuronal activity” and “neural activity” are used interchangeably herein.
Memory agents, for example CREB pathway-enhancing drugs, may enhance CREB pathway function, which is required to consolidate newly acquired information into LTM. By “enhance CREB pathway function” is meant the ability to enhance or improve CREB-dependent gene expression. CREB-dependent gene expression can be enhanced or improved by increasing endogenous CREB production, for example by directly or indirectly stimulating the endogenous gene to produce increased amounts of CREB, or by increasing functional (biologically active)
CREB. See, e.g., U.S. Pat. No. 5,929,223; U.S. Pat. No. 6,051,559; and International Publication
No. WO9611270 (published Apr. 18, 1996), which references are incorporated herein in their entirety by reference. Administration of a memory agent may decrease the training needed to yield a performance gain relative to that yielded with training alone. By “performance gain” is meant an improvement in an aspect of memory performance.
The invention provides methods for evaluating, testing and/or identifying the enhancement of a specific aspect of memory in an animal (particularly in a human or other mammal or vertebrate) (in some embodiments, in need thereof) wherein the enhancement may be due to the (a) administering to the animal a memory agent, for example one that enhances CREB pathway function; and (b) training the animal under conditions sufficient to produce an improvement in performance of a particular memory task by the animal.
Training can comprise one or multiple training sessions and is training appropriate to produce an improvement in performance of the memory task of interest. For example, if an improvement in language acquisition is desired, training would focus on language acquisition. If an improvement in ability to learn to play a musical instrument is desired, training would focus on learning to play the musical instrument. If an improvement in a particular motor skill is desired, training would focus on acquisition of the particular motor skill. The specific memory task of interest is matched with appropriate training.
The invention also provides methods for evaluating, testing and/or identifying the enhancement of memory performance in an animal caused by repeated stimulation of neuronal activity or a pattern of neuronal activity, such as that underlying a specific neuronal circuit(s), in an animal comprising (a) administering to the animal a memory agent which enhances CREB pathway function; and (b) training the animal under conditions sufficient to stimulate or induce neuronal activity or a pattern of neuronal activity in the animal. In this case, training refers to training appropriate to stimulate or induce neuronal activity or a pattern of neuronal activity in the animal.
By “multiple training sessions” is meant two or more training sessions. The memory agent can be administered before, during or after one or more of the training sessions. In a particular embodiment, the memory agent is administered before and during each training session.
Certain training protocols that can be evaluated in accordance with the present invention are known and readily available in the art. See for example, Karni, A. and Sagi, D., “Where practice makes perfect in text discrimination: evidence for primary visual cortex plasticity”,
Proc. Natl. Acad. Sci. USA, 88:4966-4970 (1991); Karni, A. and Sagi, D., “The time course of learning a visual skill,” Nature, 365:250-252 (1993); Kramer, A. F. et al., “Task coordination and aging: explorations of executive control processes in the task switching paradigm,” Acta
Psychol. (Amst.), 101:339-378 (1999); Kramer, A. F. et al., “Training for executive control:
Task coordination strategies and aging,” In Aging and Skilled Performance: Advances In Theory and Applications, W. Rogers et al., eds. (Hillsdale, N.J.: Erlbaum) (1999); Rider, R. A. and Abdulahad, D. T., “Effects of massed versus distributed practice on gross and fine motor proficiency of educable mentally handicapped adolescents,” Percept. Mot. Skills, 73:219-224 (1991); Willis, S. L. and Schaie, K. W., “Training the elderly on the ability factors of spatial orientation and inductive reasoning,” Psychol. Aging, 1:239-247 (1986); Willis, S. L. and
Nesselroade, C. S., “Long-term effects of fluid ability training in old-old age,” Develop.
Psychol., 26:905-910 (1990); Wek, S. R. and Husak, W. S., “Distributed and massed practice effects on motor performance and learning of autistic children,” Percept. Mot. Skills, 68:107-113 (1989); Verhachen, P. et al, “Improving memory performance in the aged through mnemonic training: a meta-analytic study,” Psychol. Aging, 7:242-251 (1992); Verhaeghen, P. and
Salthouse, T. A., “Meta-analyses of age-cognition relations in adulthood: estimates of linear and nonlinear age effects and structural models,” Psychol. Bull., 122:231-249 (1997); Dean, C. M. et al., “Task-related circuit training improves performance of locomotor tasks in chronic stroke: a randomized, controlled pilot trial,” Arch. Phys. Med. Rehabil., 81:409-417 (2000); Greener, J. et al., “Speech and language therapy for aphasia following stroke,” Cochrane Database Syst. Rev.,
CD000425 (2000); Hummelsheim, H. and Eickhof, C., “Repetitive sensorimotor training for arm and hand in a patient with locked-in syndrome,” Scand. J. Rehabil. Med., 31:250-256 (1999);
Johansson, B. B., “Brain plasticity and stroke rehabilitation. The Willis lecture,” Stroke, 31:223- 230 (2000); Ko Ko, C., “Effectiveness of rehabilitation for multiple sclerosis,” Clin. Rehabil., 13 (Suppl. 1):33-41 (1999); Lange, G. et al., “Organizational strategy influence on visual memory performance after stroke: cortical/subcortical and left/right hemisphere contrasts,” Arch. Phys.
Med. Rehabil., 81:89-94 (2000); Liepert, J. et al., “Treatment-induced cortical reorganization after stroke in humans,” Stroke, 31:1210-1216 (2000); Lotery, A. J. et al., “Correctable visual impairment in stroke rehabilitation patients,” Age Ageing, 29:221-222 (2000); Majid, M. J. et al., “Cognitive rehabilitation for memory deficits following stroke” (Cochrane review), Cochrane
Database Syst. Rev., CD002293 (2000); Merzenich, M. et al., “Cortical plasticity underlying perceptual, motor, and cognitive skill development: implications for neurorehabilitation,” Cold
Spring Harb. Symp. Quant. Biol., 61:1-8 (1996); Merzenich, M. M. et al., “Temporal processing deficits of language-learning impaired children ameliorated by training,” Science, 271:77-81 (1996); Murphy, E., “Stroke rehabilitation,” J. R. Coll. Physicians Lond., 33:466-468 (1999);
Nagarajan, S. S. et al., “Speech modifications algorithms used for training language learning- impaired children,” IEEE Trans. Rehabil. Eng., 6:257-268. (1998); Oddone, E. et al., “Quality
Enhancement Research Initiative in stroke: prevention, treatment, and rehabilitation,” Med. Care 38:192-1104 (2000); Rice-Oxley, M. and Turner-Stokes, L., “Effectiveness of brain injury rehabilitation,” Clin. Rehabil., 13(Suppl 1):7-24 (1999); Tallal, P. et al., “Language learning impairments: integrating basic science, technology, and remediation,” Exp. Brain Res., 123:210- 219 (1998); Tallal, P. et al., “Language comprehension in language-learning impaired children improved with acoustically modified speech,” Science, 271:81-84 (1996), which references are incorporated herein in their entirety by reference.
Accordingly, the invention also relates to methods of enhancing long term memory in an animal (particularly in a human or other mammal or vertebrate) in need of said treatment comprising (a) administering to the animal a memory agent identified, tested or evaluated by the methods of assessing, evaluating and/or testing the effectiveness of a memory agent, selecting a memory agent as a drug compound, or testing a memory agent as a long term memory enhancer, and (b) training the animal under conditions sufficient to enhance long term memory in the animal.
In one embodiment, the invention also relates to a method of treating an age-associated memory impairment in an animal in need of said treatment comprising (a) administering to the animal a memory agent identified, tested or evaluated by the methods of assessing, evaluating and/or testing the effectiveness of a memory agent, selecting a memory agent as a drug compound, or testing a memory agent as a long term memory enhancer; and (b) training the animal under conditions sufficient to enhance long term memory in the animal. .
In another embodiment, the invention relates to a method of treating a memory deficit associated with a neurodegenerative disease (e.g., Alzheimer’s disease, Parkinson’s disease,
Huntington’s disease, other senile dementia) in an animal in need of said treatment comprising (a) administering to the animal a memory agent identified, tested or evaluated by the methods of assessing, evaluating and/or testing the effectiveness of a memory agent, selecting a memory agent as a drug compound, or testing a memory agent as a long term memory enhancer; and (b) training the animal under conditions sufficient to enhance long term memory in the animal. .
In another embodiment, the invention relates to a method of treating a memory deficit associated with a psychiatric disease (e.g., depression, schizophrenia, autism, attention deficit disorder) in an animal in need of said treatment comprising (a) administering to the animal a memory agent identified, tested or evaluated by the methods of assessing, evaluating and/or testing the effectiveness of a memory agent, selecting a memory agent as a drug compound, or testing a memory agent as a long term memory enhancer; and (b) training the animal under conditions sufficient to enhance long term memory in the animal.
In another embodiment, the invention relates to a method of treating a memory deficit associated with trauma dependent loss of memory function (e.g., cerebrovascular diseases (e.g., stroke, ischemia), brain tumor, head or brain injury) in an animal in need of said treatment comprising (a) administering to the animal a memory agent identified, tested or evaluated by the methods of assessing, evaluating and/or testing the effectiveness of a memory agent, selecting a memory agent as a drug compound, or testing a memory agent as a long term memory enhancer; and (b) training the animal under conditions sufficient to enhance long term memory in the animal.
In another embodiment, the invention relates to a method of treating a memory deficit associated with a genetic defect (e.g., Rubinstein-Taybi syndrome, down syndrome) in an animal in need of said treatment comprising (a) administering to the animal a memory agent identified, tested or evaluated by the methods of assessing, evaluating and/or testing the effectiveness of a memory agent, selecting a memory agent as a drug compound, or testing a memory agent as a long term memory enhancer; and (b) training the animal under conditions sufficient to enhance long term memory in the animal.
The invention also relates to methods of therapy of a memory deficit associated with a
CNS disorder or condition in an animal having undergone neuronal stem cell manipulation (a) administering to the animal a memory agent identified, tested or evaluated by the methods of assessing, evaluating and/or testing the effectiveness of a memory agent, selecting a memory agent as a drug compound, or testing a memory agent as a long term memory enhancer; and (b)
training the animal under conditions sufficient to enhance long term memory in the animal. By “neuronal stem cell manipulation” is meant that (1) exogenous neuronal stem cells are transplanted into the brain or spinal chord of an animal or (2) endogenous neuronal stem cells are stimulated or induced to proliferate in the animal. Methods of transplanting neuronal stem cells into the brain or spinal chord of an animal are known and readily available in the art (see, e.g.,
Cameron, H. A. and McKay, R. D., Nat. Neurosci., 2:894-897 (1999); Kurimoto, Y. et al.,
Neurosci. Lett., 306:57-60 (2001); and Singh, G., Neuropathology, 21:110-114 (2001)).
Methods of stimulating or inducing proliferation of endogenous neuronal stem cells in an animal are known and readily available in the art (see, e.g., Gould, E. et al., Trends Cogn. Sci,, 3:186- 192 (1999); Gould, E. et al., Biol. Psychiatry, 48:715-20 (2000); Nilsson, M. et al, J. Neurobiol., 39:569-578 (1999); Fuchs, E. and Gould, E., Eur. J. Neurosci., 12:2211-2214 (2000); and Gould,
E. et al., Nat. Neurosci., 2:260-265 (1999)). The particular methods of transplanting neuronal stem cells into the brain or spinal chord of an animal and the particular methods of stimulating or inducing proliferation of endogenous neuronal stem cells in an animal are not critical to the practice of the invention.
The invention further relates to methods of improving or enhancing memory and/or performance in an animal with a learning, language or reading disability, or combinations of any of the foregoing, comprising (a) administering to the animal a memory agent identified, tested or evaluated by the methods of assessing, evaluating and/or testing the effectiveness of a memory agent, selecting a memory agent as a drug compound, or testing a memory agent as a long term memory enhancer; and (b) training the animal under conditions sufficient to enhance long term memory in the animal.
MEMORY AGENTS
Memory agents, as used herein, are compounds with pharmacological activity relative to memory disorders and/or memory dysfunctions, and include drugs, chemical compounds, ionic compounds, organic compounds, organic ligands, including cofactors, saccharides, recombinant and synthetic peptides, proteins, peptoids, nucleic acid sequences, including genes, nucleic acid products, and other molecules and compositions. Memory agents may, for example, enhance or impair short or long term memory. For example, memory agents may be any of the compounds set forth in United States Patent Application Serial No. 11/679,782 entitled “Therapeutic
Piperazones” and filed on February 27, 2007; United States Patent Application Serial No. 11/608,746 entitled “Indolone Compounds Useful To Treat Cognitive Impairment” and filed on
December 8, 2006; and United States Patent Application Serial No. 11/679,775 entitled “Therapeutic Compounds” and filed on February 27, 2006, United States Provisional Patent
Application Serial No. 60/942,992, entitled “Therapeutic Pyrazoloquinoline Urea Derivatives” filed on June 8, 2007, each of the above patent applications is hereby expressly incorporated by reference herein in its entirety.
A memory impairer, as used herein, are compounds with pharmacological activity relating to retained memories (for example, post-traumatic stress disorder), and include drugs, chemical compounds, ionic compounds, organic compounds, organic ligands, including cofactors, saccharides, recombinant and synthetic peptides, proteins, peptoids, nucleic acid sequences, including genes, nucleic acid products, and other molecules and compositions. The memory impairers and memory enhancers of the present invention can be used with any of the present methods and systems.
For example, memory agents can be cell permeant cAMP analogs (e.g., 8-bromo cAMP); activators of adenylate cyclase 1 (AC1) (e.g., forskolin); agents affecting G-protein linked receptor, such as, but not limited to adrenergic receptors and opioid receptors and their ligands (e.g., phenethylamines); modulators of intracellular calcium concentration (e.g., thapsigargin, N- methyl-D-aspartate (NMDA) receptor agonists); inhibitors of the phosphodiesterases responsible for cAMP breakdown (e.g., rolipram (which inhibits phosphodiesterase 4), iso-buto-metho- xanthine (IBMX) (which inhibits phosphodiesterases 1 and 2)); modulators of protein kinases and/or protein phosphatases, which mediate CREB protein activation and CREB-dependent gene expression. Memory agents can also be exogenous CREB, CREB analogs, CREB-like molecules, biologically active CREB fragments, CREB fusion proteins, and/or nucleic acid sequences encoding exogenous CREB, CREB analogs, CREB-like molecules, biologically active
CREB fragments and/or CREB fusion proteins.
Memory agents can also be CREB function modulators, and/or nucleic acid sequences encoding CREB function modulators. CREB function modulators, as used herein, have the ability to modulate CREB pathway function. By “modulate” is meant the ability to change (increase or decrease) or alter CREB pathway function.
Memory agents can be compounds which are capable of enhancing CREB function in the
CNS. Such compounds include, but are not limited to, compounds which affect membrane stability and fluidity and specific immunostimulation. In a particular embodiment, the memory agent is capable of transiently enhancing CREB pathway function in the CNS.
CREB analogs, or derivatives, are defined herein as proteins having amino acid sequences analogous to endogenous CREB. Analogous amino acid sequences are defined herein to mean amino acid sequences with sufficient identity of amino acid sequence of endogenous
CREB to possess the biological activity of endogenous CREB, but with one or more “silent” changes in the amino acid sequence. CREB analogs include mammalian CREM, mammalian
ATF-1 and other CREB/CREM/ATF-1 subfamily members.
CREB-like molecule, as the term is used herein, refers to a protein which functionally resembles (mimics) CREB. CREB-like molecules need not have amino acid sequences analogous to endogenous CREB.
Examples of memory agents can include:
CF,
CF,
N
/ N
OH
Examples of memory agents can also include:
0 (JU
CH,
OcPent
OMe wherein “Me” means methyl and “cPent” means “cyclopentyl.” The above formula embraces both enantiomers and mixtures thereof. In a particular embodiment, (HT-0712), the 3 and 5 carbons of the above formula are in the S configuration.
Examples may also include a compound having the structure:
B
T
¥; ¥y
Y, A wherein each of Yi, Y2, Y3, and Y4 is independently --H; straight chained or branched C;-
C7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C,-C; alkenyl or alkynyl; Cs-C7 cycloalkyl, or Cs-C7 cycloalkenyl; --F, --Cl, --Br, or --I; --NOy; --N3; --CNj --
ORy, --OCORy, --CORy, --NCORy, --N(Ry) 2, --CON(Ry) 2, or --COORy; aryl or heteroaryl; or anytwoof Yi, Ys, Ys and Y, present on adjacent carbon atoms can constitute a methylenedioxy group; wherein each Ry is independently --H; straight chained or branched C;-C7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C,-C7 alkenyl or alkynyl; Cs-
C7 cycloalkyl, Cs-C7 cycloalkenyl, aryl or aryl(C-Cg)alkyl; wherein A is A’, straight chained or branched C;-C7 alkyl, aryl, heteroaryl, aryl(C;-Cg)alkyl or heteroaryl(C;-Ce)alkyl; wherein A' is
O
0 Ry ~, 0 hn ’ NN. or — CHh—— Ry; wherein R; and R; are each independently H, straight chained or branched C;-C7 alkyl, -
F,--Cl, --Br, --1, --NO,, or --CN; wherein Rj is H, straight chained or branched C;-C7 alkyl, --F, --Cl, --Br, --1, --NO,, --CN, --ORg, aryl or heteroaryl; wherein Rs is straight chained or branched
C1-C7 alkyl, --N(R4) 2, --ORy or aryl; wherein Re is straight chained or branched C;-C7 alkyl or aryl; wherein B is C3-C7 cycloalkyl, Cs-C7 cycloalkenyl, adamantyl, aryl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, indolizinyl, indol-4-yl, indo1-5-yl, indol-6-yl, indol-7-yl, isoindolyl, benzo[b]furan-4-yl, benzo[b]furan-5-yl, benzo[b]furan-6-yl, benzo[b]furan-7-yl, benzo[b]thiophen-4-yl, benzo[b]thiophen-5-yl, benzo[b]thiophen-6-yl, benzo[b]thiophen-7-yl, indazolyl, benzimidazolyl, benzo[b]thiazolyl, purinyl, imidazo(2,1-b)thiazolyl, quinolinyl, isoquinolinyl, quinazolinyl, 2,1,3-benzothiazolyl, furanyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, triazolyl, thiadiazolyl, benzoxazolyl, benzisoxazolyl, cinnolinyl, quinoxalinyl, 1,8-naphthridinyl, pteridinyl, or phthalimidyl; provided however, if B is aryl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, indolizinyl, indo1-4- yl, indo1-5-yl, indol-6-yl, indol-7-yl, isoindolyl, benzo[b]furan-4-yl, benzo[b]furan-5-yl, benzo
[b] furan-6-yl, benzo[b]furan-7-yl, benzo[b]thiophen-4-yl, benzo[b]thiophen-5-yl, benzo[b]thiophen-6-yl, benzo[b]thiophen-7-yl, indazolyl, benzimidazolyl, benzo[b]thiazolyl, purinyl, imidazo[2,1-b]thiazolyl, quinolinyl, isoquinolinyl, quinazolinyl, 2,1,3-benzothiazolyl, furanyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, triazolyl, thiadiazolyl, benzoxazolyl, benzisoxazolyl, cinnolinyl, quinoxalinyl, 1,8- napthyridinyl, pteridinyl, or phthalimidyl the carbon atom or carbon atoms ortho to the nitrogen atom of the imine bond may only be substituted with one or more of the following --F, --Cl, --Br, --1, --CN, methyl, ethyl or methoxy; wherein n is an integer from 1 to 4 inclusive, and wherein aryl is phenyl or napthyl, including phenyl and napthyl substituted with one or more of the following: -F, -Cl, -Br, -1, -NO,, -CN, straight chained or branched C;-C; alkyl, straight chained or branched C;-C7 monofluoroalkyl, straight chained or branched C;-C7 polyfluoroalkyl, straight chained or branched C;,-C7 alkenyl, straight chained or branched C,-C7 alkenyl, C3C7 cycloalkyl,
C3-C7 monofluorocycloalkyl, C3-C7 polyfluorocycloalkyl, Cs-C7 cycloalkenyl, -OR4, SRy, -
OCORy, -CORy, -NCORy, -COzR4, -CON(R4); or (CH2)p-O-(CHy)m.-CHs.
In some embodiments A is aryl, heteroaryl, or heteroaryl (C;-Cs)alkyl; and wherein aryl is substituted with --F, --Cl, --Br, --1, --NO,, --CN, straight chained or branched C;-C7 alkyl, straight chained or branched C;-C7; monofluoroalkyl, straight chained or branched C;-C polyfluoroalkyl, straight chained or branched C,-C7 alkenyl, straight chained or branched C,-C7 alkynyl, C3-C; cycloalkyl, C3-C7; monofluorocycloalkyl, Cs-C; polyfluorocycloalkyl, Cs-C5 cycloalkenyl, --N(R4)2, --ORy4, --SR4, --OCORy, --COR4, --NCORy, --CO2R4, --CON(R4); or -- (CH2)sO(CH2)mCH3. A may also be aryl, heteroaryl, heteroaryl(C;-Cg)alkyl or --(CH;),--CC--
R4; wherein the aryl is substituted with --OH. In other embodiments, wherein A is A" and A’ is
Ry “AN
In other embodiments each of Yi, Y», Y3, and Yy4 is independently --H; straight chained or branched C;-C7 alkyl, --CFs, --F,--C1, --Br, --1, --OR4, --N(R4)2, or --CON(R4)2; wherein each
R4 is independently --H; straight chained or branched C;-C7 alkyl, --CFs, or phenyl; wherein A is
A’, straight chained or branched C;-C; alkyl, aryl, heteroaryl, aryl(C;-Ce)alkyl or heteroaryl(C;-
Cg)alkyl; and wherein A' is 2
TRE Somw,
In certain embodiments, B is C3-C7 cycloalkyl or adamantyl. In other embodiments, B is pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, indolizinyl, indol-4-yl, indol-5-yl, indo1- 6- yl, indo1-7-yl, isoindolyl, benzo[b]furan-4-yl, benzo[b]furan-5-yl, benzo[b]furan-6-yl, benzo[b]furan-7-yl, benzo[b]thiophen-4-yl, benzo[b]thiophen-5-yl, benzo[b]thiophen-6-yl, benzo[b]thiophen-7-yl, indazolyl, benzimidazolyl, benzo[b]thiazolyl, purinyl, imidazo[2,1- b]thiazolyl, quinolinyl, isoquinolinyl, quinazolinyl, 2,1,3-benzothiazolyl, furanyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, triazolyl, thiadiazolyl, benzoxazolyl, benzisoxazolyl, cinnolinyl, quinoxalinyl, 1,8-napthyridinyl, pteridinyl, or phthalimidyl. In other embodiments B is aryl or is phenyl and the phenyl is optionally substituted with one or more of the following: --F, --Cl, --Br, --CF3, straight chained or branched C;-C7 alkyl, --ORy, --CORy, --NCORy, --CO,R4, or --CON(R4),.
Further examples include compounds have the following structures:
Sagum . on b
A
PN
J -
Nn PN Cl; mr 7 ~ Rl ~ 2 es Niwa i:
TN i wi pS LA, 2
Sa
A)
OQ
N
8
OH
= wl
A
J
A Bb
PN
3 9 a
Tr
NAL . Ti 3 [NA 7
NA A,
Further examples include a compound having the structure: ~ | i
Fang, wg, od
Pr RNY ea To
EY
4 wherein each of Yi, Y,, Y3, and Y4 is independently --H; straight chained or branched C;- (C7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C,-C7 alkenyl or alkynyl; Cs-C7 cycloalkyl or Cs-C7 cycloalkenyl; --F, --Cl1, --Br, or --1; --NO»; --N3; --CN; --ORy, --SRy4, --OCORy, --CORy, --NCORy, --N(R4)2, --CON(R4)2, or --COORy; aryl or heteroaryl; or any two of Yy, Y,, Y3 and Y, present on adjacent carbon atoms can constitute a methylenedioxy group; wherein each Ry is independently --H; straight chained or branched C;-C; alkyl,
monofluoroalkyl or polyfluoroalkyl; straight chained or branched C,-C7 alkenyl or alkynyl; Cs-
C7 cycloalkyl, Cs-C7 cycloalkenyl, aryl or aryl(C-Cg)alkyl; wherein A is A’, straight chained or branched C;-C; alkyl, aryl, heteroaryl, aryl(C;-Cg)alkyl or heteroaryl(C;-Cg)alkyl; wherein A' is
I [a] A an oa Nog “ 3 1 i - “e ¥ pe ks ~ Ry } * “b L
Mn Pe : poo ee 0 open REE Rg eh Spm, me to wherein R; and R; are each independently H, straight chained or branched C;-C7 alkyl, -
F, --Cl, --Br, --1, --NO,, or --CN; wherein Rj is H, straight chained or branched C;-C; alkyl, --F, --Cl, --Br, --1, --NO,, --CN, --ORg, aryl or heteroaryl; wherein Rs is straight chained or branched
C1-C7 alkyl, --N(R4)2, --OR4 or aryl; wherein Rg is straight chained or branched C;-C7 alkyl or aryl; wherein B is aryl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, indolizinyl, indol- 4-yl, indol-5-yl, indol-6-yl, indol-7-yl, isoindolyl, benzo[b]furan-4-yl, benzo[b]furan-5-yl, benzo[b]furan-6-yl, benzo[b]furan-7-yl, benzo[b]thiophen-4-yl, benzo[b]thiophen-5-yl, benzo[b]thiophen-6-yl, benzo[b]thiophen-7-yl, indazolyl, benzimidazolyl, benzo[b]thiazolyl, purinyl, imidazo[2,1-b]thiazolyl, quinolinyl, isoquinolinyl, quinazolinyl, 2,1,3-benzothiazolyl, furanyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, triazolyl, thiadiazolyl, benzoxazolyl, benzisoxazolyl, cinnolinyl, quinoxalinyl, 1,8-
napthyridinyl, pteridinyl, or phthalimidyl; provided however, that the carbon atom or carbon atoms ortho to the nitrogen atom of the imine bond may only be substituted with one or more of the following --F, -Cl, --Br, --1, --CN, methyl, ethyl or methoxy; wherein n is an integer from 1 to 4 inclusive; wherein aryl is phenyl or napthyl, including phenyl and napthyl substituted with one or more of the following: -F, -Cl, -Br, -1, -NO,, -CN, straight chained or branched C;-C alkyl, straight chained or branched C;-C7; monofluoroalkyl, straight chained or branched C;-C polyfluoroalkyl, straight chained or branched C,-C7 alkenyl, straight chained or branched C,-C7 alkynyl, Cs-C; cycloalkyl, C;-C7 monofluorocycloalkyl, Cs-C7 polyfluorocycloalkyl, Cs-Cy cycloalkenyl, -OR4, SRy4, -OCORy, -COR4, -NCORy, -CO2R4, -CON(R4); or (CH2)p-O-(CH2)pm-
CHas; or a pharmaceutically acceptable salt thereof. In some embodiments, each of Y, Ys, Ys, and Y is independently --H; straight chained or branched C;-C7 alkyl, --CF;, --F, --Cl, --Br, --1, - -ORy4, --N(Ry)2, or --CON(R4)..
In some embodiments, A is aryl, heteroaryl, heteroaryl(C;-Cg)alkyl or --(CH;),--CC--Ry; wherein the aryl is substituted with —OH. In other embodiments, A is aryl, heteroaryl, or heteroaryl(C;-Cg)alkyl; and wherein aryl is substituted with --F, --Cl, --Br, --1, --NO,, --CN, straight chained or branched C;-C5 alkyl, straight chained or branched C;-C7 monofluoroalkyl, straight chained or branched C;-C7 polyfluoroalkyl, straight chained or branched C,-C7 alkenyl, straight chained or branched C,-C; alkynyl, C3-C7 cycloalkyl, C3-C7; monofluorocycloalkyl, Cs-
C5 polyfluorocycloalkyl, Cs-C; cycloalkenyl, --N(Ry),, --ORy, --SRy, --OCORy, --CORy, --
COzRy4, --CON(Ry) 2 or --(CH2),O(CH2)mCHs. A may also be aryl or aryl(C;.Ce)alkyl. In other embodiments, A is A', straight chained or branched C;-C7 alkyl, aryl, heteroaryl, aryl(C;-
Cs)alkyl or heteroaryl(C;-Ce)alkyl; and A' is
Mg ; = So
The compounds described herein may be enantiomerically and/or diastereomerically pure. The may also be a pure Z imine isomer or a pure Z alkene isome, or a pure E imine isomer or a pure E alkene isomer.
Additional examples include:
I'l a ¢
Ven # ix
Sp. x ER
J
Cr5- o
A
=F | - wt ne J . ¢ ho + #5 oS i
Sy
2 x ~_
Cr A - 0
Additional examples may include a compound of the following formula:
Ar 4
R, NN
Roh A m0 1 EN A
Ry 7 N° Re fe oh 07 NT i
Rs or a pharmaceutically acceptable salt thereof, wherein:
Ri, Ry, Ry, and Ry are each independently selected from the group consisting of hydrogen, hydroxy, halo, cyano, -CONR,R, -NR Ry, hydroxy(C;-Ce)alkyl , aryl, heteroaryl, heterocycle, amino(C;-Ce)alkyl, (C1-Ce)alkyl optionally substituted with up to 5 fluoro, and (C;-
Cs)alkoxy optionally substituted with up to 5 fluoro; each R, and Ry, are independently hydrogen , (C;-Cg)alkyl, aryl, (C;-Cs)alkylOC(O)-, or arylOC(O)-, or R, and Ry, are taken together with the nitrogen to which they are attached to form a heterocycle group optionally substituted with one or more Ry; wherein the heterocycle group optionally include one or more groups selected from O (oxygen), S(O),, and NR; each z is an integer selected from 0, 1, and 2; each R. is independently hydrogen, (C,-Cg)alkenyl, (Co-Ce)alkynyl, -C(O)O(C;-Ce)alkyl, -C(O)Oaryl, (C-Cg)alkoxy(C;-Cg)alkyl, (C;-Cg)alkylO(CHy)y,, hydroxy(C-Ce)alkyl, aryl, heteroaryl, Heterocycle, arylO(C;-Ce)alkyl, -C(O)NR(C;-Ce)alkyl, -C(O)NRgaryl, -S(O),(Cs-
Ce)alkyl, -S(O), aryl, -C(O)(C;-Co)alkyl, aryl C(O)-, (C;-Ce)alkyl optionally substituted with up to 5 fluoro, or (C;-Cs)alkoxy optionally substituted with up to 5 fluoro; each m is an integer selected from 2, 3, 4, 5, and 6; each Ry is independently selected from the group consisting of hydrogen, halo, oxo, hydroxy, -C(O)NR Rp, -NR,Ryp, hydroxy(C;-Ce)alkyl, aryl, aryl(C;-Ce)alkyl, (C;-Cg)alkyl optionally substituted with up to 5 fluoro, and (C;-Cs)alkoxy optionally substituted with up toS fluoro;
Rc and R; are each independently selected from the group consisting of hydrogen, (C;- Cg)alkyl, aryl, -S(0O),(C1-Ce)alkyl, -S(O),aryl, -CONRg(C;-Cgalkyl), (C;-Ce)alky 1C(O)-, aryl C(O)-, (C1-Ce)alkylOC(O)-, and arylOC(O)-;
R; is hydrogen or (C;-Cg)alkyl;
Rs and Rg are each independently selected from the group consisting of hydrogen, (C;-
Ce)alkyl, (Cy-Ce)alkenyl, (C,-Ces)alkynyl, and aryl, or Rs and Re are taken together with the nitrogen to which they are attached to form a heterocycle group optionally substituted with one or more Ry; wherein the heterocycle group optionally include one or more groups selected from
O (oxygen), S(O)z, and NR;
R7 is selected from the group consisting of hydrogen, hydroxy, halo, hydroxy(C;-
Ce)alkyl, (C;-Cg)alkyl optionally substituted with up to 5 fluoro, and (C;-Ce)alkoxy optionally substituted with up to 5 fluoro;
Ar is aryl, or heteroaryl, each optionally substituted with one or more Rg; and each Rg is independently hydrogen, halo, CF;, CF,H, hydroxy, cyano, nitro,( C;-Cg)alkyl, hydroxy(C;-Ce)alkyl, (C-Cs)alkoxy, -NRiRy, aryl, heteroaryl or heterocycle.
Other examples include the compound of following formula:
JF xe \/
Ra. rn” S0
PY
Ry oy wv CRs
Ry a N Rs and pharmaceutically acceptable salts thereof.
Rs and Rs may, for example, together with the nitrogen to which they are attached, form a piperidinyl, pyrrolidinyl, morpholinyl, or thiomorpholinyl ring in the compound of the above formula.
Yet further examples include a compound of the following formula:
J
R, NY
Ry A HL =o
I TX A
Ry °F N Ry oY
MX
Yin and pharmaceutically acceptable salts thereof, wherein: X is N(R.), O (oxygen), C(Rq)2, or S(O); z is an integer selected from 0, 1, and 2; each Ry is independently selected from the group consisting of hydrogen, halo, oxo, hydroxy, -C(O)NR:Ry, -NR:Ryp, hydroxy(C;-Cs)alkyl, aryl, aryl(C;-Cg)alkyl, (C;-Cg)alkyl optionally substituted with up to 5 fluoro , and (C;-Cg)alkoxy optionally substituted with up to 5 fluoro; and n is an integer selected from 0, 1, and 2; with the proviso that when n = 0 then X is C(Rq)a.
Other examples include a compound of the following formula:
Ay i N= 8 pg!
Ry A Ape ad I )
RN NR
}
Ry
Fu 7 NTA
Rel a
OR and pharmaceutically acceptable salts thereof.
Other examples include a compound of the following formula: [> Rg
R; NN
Ba age” Ad A
LA CR; : Ng
Ra oP
Rymp x
REA bin and pharmaceutically acceptable salts thereof, wherein nis 0, 1, or 2.
In some embodiments, R; is Methyl, fluro, or OMe. In some embodiments, Rs is Methyl, fluro, or OMe. In some embodiments, R, and Rj; are fluoro. In another embodiment, R; and Rj are Methyl.
Other examples include a compound of the following formula:
FR y {x
Nona
So
Rg NN
XX
RE NT OR
. Ra
Re A
Lae TR, and pharmaceutically acceptable salts thereof.
Other examples include a compound of the following formula:
Yo oo s¥
Soop
Re NN
Ry A A 0
Ry hl - Ry
R] ali SE He 4 oF NE
Rs and pharmaceutically acceptable salts thereof, wherein each Y is independently N or
C(Rg). In some embodiments, Rs and Rg, together with the nitrogen to which they are attached,
form a piperidinyl, pyrrolidinyl, morpholinyl, or thiomorpholinyl ring, each optionally substituted with one or more Ry.
Further examples include a compound of the following formula:
J % ¥ ¥ ¢ =
RB, NN
EN A A ergy
OY ON Tw
Ra A PEN Ru oF TN .
Ret 4
Ru and pharmaceutically acceptable salts thereof.
In some embodiments n can be 0, 1 or 2. In some embodiments, R, may be Methyl, fluoro or OMe. In some embodiments, R3 can be Methyl, fluoro or OMe. In some embodiments,
R, and Rj; can be fluoro. In another embodiment, R; and R3 can be Methyl.
Additional examples include a compounds of the formulas:
Ye
Fn ¥ ¥
FA
Te = EN a
REY CR,
R Ha tao “or Ky “ wo
FR
NOS
Named 7 qe NN ‘ t 3
Ra A A eg
LX
R; ¥ Ry
Ra oF Su “NN
Ry x
Ser i owed
Ry nN ] Po ee
Ra oY i if i
BON Se Ry 3 Fig
Ra oP “I
Rgp~
Ll, X
TF au and ~H
FN
No
J “B ’, NN
Re, A Ma ok
Ry LL “Ry ; : Rg
Re oo NIN
Rep
LX wo, and pharmaceutically acceptable salts thereof.
Examples also include a compound of the following formula:
By ~ Xx hd ee
Z wherein: R; is H, (C;-Cg)alkyl, (C1-Ce)alkoxy, (C;-Ce)alkanoyl, (C;-Ce)alkoxycarbonyl, (C;-Ce)alkanoyloxy, (Cs-Cg)cycloalkyl, (C3-Cg)eycloalkyl((C;-Ceg)alkyl, halo(C;-Cg)alkyl, aryl, aryl(C;-Ce)alkyl, aryl(C;-Cs)alkoxy, aryl(C;-Ce)alkanoyl, het, het(C;-Cg)alkyl, het(C;-Ce)alkoxy, or het(C;-Cs)alkanoyl; nis 1 or 2; mis 1 or?2;
Wis O, S, or two hydrogens;
X is 0 or N-Y-Ry;
Y is a direct bond, -CH,-, -C(=0)-, -C(=S)-, -0-, -C(=0)O-, -OC(=0)-, -C(=0)NR,-, -S-, -
S(=0)-, -S(=0)2-, or -S(=0)2NR,-;
Ry is H, (Ci-Co)alkyl, (C;-Cg)alkoxy, (Ci-Cs)alkanoyl, hydroxy, (Cs-Csg)cycloalkyl, (Cs-
Cs)cycloalkyl(C;-Ceg)alkyl, halo(C;-Ce)alkyl, hydroxy(C;-Ce)alkyl, (C;-Cs)alkoxycarbonyl, carboxy, aryl, aryl(C;-Cs)alkyl, het, NR4R., -C(=O)NR4R., NR4R, (C;-Cg)alkyl, or het(C;-
Cg)alkyl;
Ra is H, (C;-Ce)alkyl, (C3-Cs)cycloalkyl, (C1-Ce)alkoxy(C,-Ce)alkyl, or (Cs-
Cs)cycloalkyl(C;-Ce)alkyl;
Z.1s a phenyl ring substituted with one or more substituents independently selected from (C1-Ce)alkyl, halo(C;-Ce)alkyl, (Cs-Cg)ecycloalkyl, (C3-Cg)eycloalkyl(Ci-Ce)alkyl, (C;- Cg)alkoxy, halo(C;-Cg)alkoxy, (Cs;-Cg)cycloalkyloxy, and (Cs-Cg)cycloalkyl(C;-Cg)alkoxy; or Z is a phenyl ring that is fused to a saturated, partially unsaturated, or aromatic, mono- or bicyclic ring system comprising from about 3 to about § atoms selected from carbon, oxygen, and NR, wherein the mono- or bicyclic ring system of Z is optionally substituted with one or more Ry, and wherein the phenyl ring that is fused to the mono- or bicyclic ring system is optionally substituted with one or more substitaents independently selected from (C;-Ce)alkyl, halo(C;-
Ce)alkyl, (C3-Cs)cycloalkyl, (Cs-Cs)cycloalkyl(C-Ce)alkyl, (Ci-Ces)alkoxy, halo(C,-Ce)alkoxy, (Cs-Cg)cycloalkyloxy, and (Cs-Cg)cycloalkyl(C,-Ce)alkoxy;
Ry, is absent, H, (C;-Cg)alkyl, (Cs-Cs)cycloalkyl, (Ci-Ce)alkoxy(C,-Ce)alkyl, or (Cs-
Cs)cycloalkyl(C;-Ce)alkyl;
R., is (C;-Ceg)alkyl, (C;-Ceg)alkoxy, (C1-Ces)alkanoyl, (C1-Ce)alkoxycarbonyl, (Ci-
Cs)alkanoyloxy, (Cz-Cs)cycloalkyl, (Cs-Cg)cycloalkyl(Ci-Ces)alkyl, halo(C;-Ce)alkyl, aryl, aryl(C;-Ce)alkyl, aryl(C;-Cs)alkoxy, aryl(C;-Ce)alkanoyl, het, het(C;-Cg)alkyl, het(C;-Ce)alkoxy, or het(C;-Cg)alkanoyl; each R4 and R. is independently H, hydroxy, (C;-Cg)alkyl, (C;-Ce)alkenyl, (C,-
Cg)alkynyl, (C;-Ceg)alkoxy, (C,-Cs)alkenyloxy, (Ca-Ce)alkynyloxy, (Ci-Ce)alkanoyl, (C;-
Cs)alkoxycarbonyl, (Cs-Cs)cycloalkyl, (Cs-Cs)cycloalkyl(Ci-Ce)alkyl, aryl, aryl(C;-Ce)alkyl,
NR(Rg, or aryl(C;-Ce)alkoxy; and each Rr and Rg is independently H, (Ci-Cg)alkyl, (C;-Ce)alkoxy, (Ci-Ce)alkanoyl, (Ci-
Cg)alkoxycarbonyl, (C3;-Cg)cycloalkyl, (Cs-Cg)eycloalkyl(C;-Cg)alkyl, aryl, aryl(C;-Ce)alkyl, or aryl(C;-Ce)alkoxy; or Rr and Rg together with the nitrogen to which they are attached form a pyrrolidino, piperidino , piperazino , morpholino, or thiomorpholino ring; wherein any aryl or het of R; and Ry is optionally substituted with one or more substitutents independently selected from (C;-Cg)alkyl, phenyl, (C;-Cg)alkoxy, (C;-Ce)alkanoyl, (C-Ce)alkoxycarbonyl, (C;-Cs)alkanoyloxy, (Cs-Cs)cycloalkyl, (Cs-Cg)cycloalkyl(C;-Ce)alkyl, halo(C;-Ce)alkyl, (C3-Cs)cycloalkyloxy, (Cs-Cs)cycloalkyl(Ci-Ces)alkoxy, halo(C,-Cs)alkoxy, cyan, nitro, halo, carboxy or NRgRe; and wherein the ring containing X is optionally substituted on carbon with one or more halo, (C;-Cg)alkyl, or (C;-Cg)alkoxy.
Including any pharmaceutically acceptable salt thereof.
Other examples include a compound of the following formula:
Yl
SOY R® pa-N a Ay ood 5) x
RY nl wherein: R! is (C1-Co)alkyl, (C; -Cg)haloalkyl, or aryl , unsubstituted or substituted with one or more Re; one of R? and R® is absent and the other is hydrogen, (C;-Ce)alkyl, halo(C;-Ce)alkyl, hydroxy(C;-Ce)alkyl, (C3-Cg)cycloalkyl, amino(C,-Ce)alkyl, or aryl, each unsubstituted or substituted with one or more groups selected from alkyl, halo, haloalkyl or nitro, Het, (Cs-
Cs)cycloalkyl(C;-Cg)alkyl, aryl(C;-Ce)alkyl, (C;-Cs) or Het(C-Cg)alkyl;
B is aryl, thiophene, heteroaryl, furan or pyrrole;
X is -C(=0), -C(-S), -C(R*),, -C(OH)-, or -S(0),; each z is independently 0, 1, or 2;
Y is RY, -N(R*),, -OR", -SR*, or -C(R")3; each R* is independently selected from the group consisting of hydrogen, (CCs) alkyl, (Cy-Co)alkenyl, (C,-Co)alkynyl, (C;-Ce)alkoxy, (C;-Ce)alkanoyl, (C;Cg)alkoxycarbonyl, (Cs-
Cs)cycloalkyl, (Cs-Cg)cycloalkyl(C;-Ceg)alkyl, (C-Cg)alkoxy(C,-Cg)alkyl, hydroxy(C,-Cg)alkyl, cyano(C;-Ce)alkyl, (C;-Ceg)alkthio(Cz-Ce)alkyl, aryl, aryl(Ci-Ce)alkyl, aryloxy(C,-Ce)alkyl, halo(C,-Cg)alkyl, (C;-Ce)alkoxycarbonyl(C,Ce)alkyl, NR,Ry, Het, or Het(C;-Cg)alkyl, unsubstituted or substituted with one or more or two R* groups are taken together with the atom to which they are attached to form aryl, Het, or a saturated or unsaturated 3-8 membered monocyclic or 8-12 membered bicyclic ring system comprising carbon atoms and optionally comprising one or more additional heteroatoms selected from O, S(O),, and NR, wherein each ring system is optionally substituted with one or more Rg; each R, and Ry, is independently hydrogen or (C;-Cg)alkyl; each R,, is independently hydrogen, aryl, S(O),, (C-Cg)alkanoyl, hydroxy(C;-Ce)alkyl, alkoxy(C;-Cs)alkyl, Het, (C;-Cg)alkoxycabonyl or (C;-Cg)alkyl, unsubstituted or substituted with one or more subtituents Re; each Ry is independently halo, hydroxy, cyano, nitro, azido, amino, (C;-Ce)alkylamino, amino(C;-Cg)alkyl, amido, (C;-Cg)alkyamido, aryl amido, carboxylic acid, (C;-Cg)alkyl, hydrox y(C;-Cg)alkyl, halo(C;-Cg)alkyl, (C;-Cs)alkoxy, halo(C;-Cg)alkoxy, (C;-Cs)alkanoyl, (C;-
Cs)alkoxycarbonyl, carboxy, (C;-Cs)alkanoyloxy, Het, aryl, Het(C;-Ce)alkyl, or aryl(C;- Ce)alkyl, (Ci-Ce)alkylaryl, sulfonyl, sulfonamido, urea, carbamate, unsubstituted or substituted with one or more substituents Re, or two Rgq come together with the atom to which they are attached to form a ketone or spirocyclic carbocyclic or heterocyclic ring, or two Rq come together with the atoms to which they are attached to form a bicyclic carbocyclic or heterocyclic ring, wherein each spirocyclic or bicyclic ring isunsubstituted or substituted with one or more halo, hydroxy, cyano, nitro, azido, (C;-Cg)alkyl, hydroxy(C;-Cg)alkyl, halo(C;-Cs)alkyl, (C;-
Cs)alkoxy, halo(C;-Cs)alkoxy, (Ci-Ces)alkanoyl, (C;-Ces)alkoxycarbonyl, carboxy, (C;- Cgalkanoyloxy, NR{Rg, RiR;NC(=0)-,phenyl, or phenyl(C;-C¢)alkyl, sulfonyl, sulfonamido, urea, carbamate, wherein Rr and R, together with the nitrogen to which they are attached form a piperidino, pyrrolidino, morpholino, or thiomorpholino ring, unsubstituted or substituted with one or more substituents R; each R,, is independently selected from halo, hydroxy, cyano, nitro, azido, (C;-Ce)alkyl,
Het, aryl, (Ci-Ce)alkylHet, (Ci-Ce)alkylaryl, (C1-Ce)alkylHet(C;-Ce)alkyl, (C1-Ce)alkylaryl(C;-
Ce)alkyl, (Ci-Ce)haloalkyl, (Ci-Ce)alkoxy, (Ci-Ce)haloalkoxy, (C1Cs)alkanoyl, (C;-
Cs)alkoxycarbonyl, carboxy, and (C;-Cg)alkanoyloxy;
Ris H, (C;-Co)alkyl, (C;-Ce)alkenyl, (C;-Cg)alkynyl, aryl(C;-Ce)alkyl; and cach R% is H, (C;-Cg)alkyl, amino, amido, keto, or aryl(C;-Cg)alkyl, with the proviso that when B is thiophene, R'is trifluoromethyl, R%is methyl, R? and R® are absent, Ris H, X is
C(=0) and Y is N(R*),, both R* are not methyl.
Additional examples include a compound of the following formula:
R* 5 =
RS Ey 2 Fuad wherein R! is (C;-Ce)alkyl, (C-Cg)haloalkyl, or aryl, unsubstituted or substituted with one or more Re; one of R? and R® is absent and the other is hydrogen, (C;-Ce)alkyl, halo(C;-Ce)alkyl, hydroxy(C;-Ce)alkyl, (Cs-Cs)cycloalkyl, amino(C,-Ce)alkyl, or aryl, each unsubstituted or substituted with one or more groups selected from alkyl, halo, haloalkyl or nitro, Het, (Cs-
Cs)cycloalkyl(C;-Cg)alkyl, aryl(C;-Ce)alkyl, (C;-Cs) or Het(C-Cg)alkyl; each of Z', 7°, and 7 is independently C(R®),, N(R®)q, O, or S, wherein if Z' is N(R®),,
O, or S, at least one of 7} or 7? must be N(R, O,orS;
each p is independently 0, 1, or 2; each q is independently O or 1;
X is -C(=0), -C(=S), -C(RY);, or -S(O)L; each z is independently 0, 1, or 2;
Y is RY, -N(R*z, -OR?, -SR*, or -C(R*)s; each R* is independently selected from the group consisting of hydrogen, (C;-Cs)alkyl, (Cy-Co)alkenyl, (Cy-Co)alkynyl, (Ci-Ce)alkoxy, (C;-Ce)alkanoyl, (C;-Ce)alkoxycarbonyl, (Cs-
Cs)cycloalkyl, (Cs-Cg)cycloalkyl(C;-Ceg)alkyl, (C-Cg)alkoxy(C,-Cg)alkyl, hydroxy(C,-Cg)alkyl, cyano(C;-Ce)alkyl, (C;-Cg)alkthio(C,-Cg)alkyl, aryl, aryl(C;-Cg)alkyl, aryloxy(C,-Cg)alkyl, halo(C»-Ce)alkyl, (Ci-Ce)alkoxycarbonyl(C;-Ce)alkyl, NR,Ry, Het, or Het(C;-Ce)alkyl, wherein each alkyl, aryl, or Het is unsubstituted or substituted with one or more Rg, or two R* groups are taken together with the atom to which they are attached to form aryl, Het, or a saturated or unsaturated 3-8 membered monocyclic or 8-12 membered bicyclic ring system comprising carbon atoms and optionally comprising one or more additional heteroatoms selected from O,
S(O), and NR, wherein each ringsystem is optionally substituted with one or more Rg; each R, and Ry, is independently hydrogen or (C;-Cg)alkyl; each R. is independently hydrogen, aryl, S(O),, (C;-Cg)alkanoyl, hydroxy(C;-Ce)alkyl, alkoxy(C; -Ce)alkyl, Het, (C;-Cg)alkoxycabonyl or (C;-Cg)alkyl, unsubstituted or substituted with one or more substituents Re; each Ry is independently halo, hydroxy, cyano, nitro, azido, amino, (C;-Ce)alkylamino, amino(C;-Ce)alkyl, amido, (C;-Cs)alkyamido, aryl amido, carboxylic acid, (C;-Ce)alkyl, hydrox y(C;-Cg)alkyl, halo(C;-Cg)alkyl, (C;-Cg)alkoxy, halo(C;-Cg)alkoxy, (C;-Cg)alkanoyl, (C;-
Cg)alkoxycarbonyl, carboxy, (C;-Cg)alkanoyloxy, Het, aryl, Het(C;-Cg)alkyl, or aryl(C;-
Ce)alkyl, (Ci-Ce)alkylaryl, sulfonyl, sulfonamide, urea, carbamate, unsubstituted or substituted with one or more substituents Re, or two R4 come together with the atom to which they are attached to form a ketone or spirocyclic carbocyclic or heterocyclic ring, or two Rq come together with the atoms to which they are attached to form a bicyclic carbocyclic or heterocyclic ring, wherein each spirocyclic or bicyclic ring is unsubstituted or substituted with one or more halo, hydroxy, cyano, nitro, azido, (C;-Cg)alkyl, hydroxy(C;-Cg)alkyl, halo(C;-Cs)alkyl, (C;- Cs)alkoxy, halo(C;-Cs)alkoxy, (Ci-Ce)alkanoyl, (C;-Ce)alkoxycarbonyl, carboxy, (C;-
Ce)alkanoyloxy, NRiR,, RiIR,;NC(=0)-, phenyl, or phenyl(C;-Cs)alkyl, sulfonyl, sulfonamido,
urea, carbamate, wherein Rr and R, together with the nitrogen to which they are attached form a piperidino, pyrrolidino, morpholino, or thiomorpholino ring, unsubstituted or substituted with one or more substituents R; each R. is independently selected from halo, hydroxy, cyano, nitro, azido, (C;-Ce)alkyl,
Het, aryl, (C;-Ce)alkylHet, (C1-Ce)alkylaryl, (C;-Ce)alkylHet(C;-Ce)alkyl, (C;-Ce)alkylaryl(Cl-
Ce)alkyl, (Ci-Ce)haloalkyl, (C;-Ce)alkoxy, (C;-Ce)haloalkoxy, (Cl-Ces)alkanoyl, (CI-
Cs)alkoxycarbonyl, carboxy, and (C;-Cg)alkanoyloxy;
Ris H, (C;-Cg)alkyl, aryl(C,-Ce)alkyl; and cach R% is H, (C;-C¢)alkyl, amino, amido, keto, or aryl(C;-Cg)alkyl; with the proviso that when X is -C(=0), Y is N(R*z, Z; is O, Z?is N, and Z3 is CH, both R* of Y are not H.
Biologically active polypeptide fragments of CREB can include only a part of the full- length amino acid sequence of CREB, yet possess biological activity. Such fragments can be produced by carboxyl or amino terminal deletions, as well as internal deletions.
Fusion proteins comprise a CREB protein as described herein, referred to as a first moiety, linked to a second moiety not occurring in the CREB protein. The second moiety can be a single amino acid, peptide or polypeptide or other organic moiety, such as, without limitation, a carbohydrate, a lipid or an inorganic molecule.
Nucleic acid sequences are defined herein as heteropolymers of nucleic acid molecules.
The nucleic acid molecules can be double stranded or single stranded and can be a deoxyribonucleotide (DNA) molecule, such as cDNA or genomic DNA, or a ribonucleotide (RNA) molecule. As such, the nucleic acid sequence can, for example, include one or more exons, with or without, as appropriate, introns, as well as one or more suitable control sequences.
In one example, the nucleic acid molecule contains a single open reading frame which encodes a desired nucleic acid product. The nucleic acid sequence can be operably linked to a suitable promoter.
A nucleic acid sequence encoding a desired CREB protein, CREB analog (including
CREM, ATF-1), CREB-like molecule, biologically active CREB fragment, CREB fusion protein or CREB function modulator can be isolated from nature, modified from native sequences or manufactured de novo, as described in, for example, Ausubel et al., Current Protocols in
Molecular Biology, John Wiley & Sons, New York (1998); and Sambrook et al., Molecular
Cloning: A Laboratory Manual, 2nd edition, Cold Spring Harbor University Press, New York. (1989). Nucleic acids can be isolated and fused together by methods known in the art, such as exploiting and manufacturing compatible cloning or restriction sites.
Typically, the nucleic acid sequence will be a gene which encodes the desired CREB protein, CREB analog, CREB-like molecule, CREB fusion protein or CREB function modulator.
Such a gene is typically operably linked to suitable control sequences capable of effecting the expression of the CREB protein or CREB function modulator, preferably in the CNS. The term “operably linked”, as used herein, is defined to mean that the gene (or the nucleic acid sequence) is linked to control sequences in a manner which allows expression of the gene (or the nucleic acid sequence). Generally, but not always, operably linked means contiguous.
Control sequences include a transcriptional promoter, an optional operator sequence to control transcription, a sequence encoding suitable messenger RNA (mRNA) ribosomal binding sites and sequences which control termination of transcription and translation. In a particular embodiment, a recombinant gene (or a nucleic acid sequence) encoding a CREB protein, CREB analog, CREB-like molecule, biologically active CREB fragment, CREB fusion protein or
CREB function modulator can be placed under the regulatory control of a promoter which can be induced or repressed, thereby offering a greater degree of control with respect to the level of the product.
As used herein, the term “promoter” refers to a sequence of DNA, usually upstream (57) of the coding region of a structural gene, which controls the expression of the coding region by providing recognition and binding sites for RNA polymerase and other factors which may be required for initiation of transcription. Suitable promoters are well known in the art. Exemplary promoters include the SV40 and human elongation factor (EFI). Other suitable promoters are readily available in the art (see, e.g., Ausubel et al., Current Protocols in Molecular Biology,
John Wiley & Sons, Inc., New York (1998); Sambrook et al., Molecular Cloning: A Laboratory
Manual, 2nd edition, Cold Spring Harbor University Press, New York (1989); and U.S. Pat. No. 5,681,735).
Memory agents can enhance CREB pathway function by a variety of mechanisms. For example, a memory agent can affect a signal transduction pathway which leads to induction of CREB-dependent gene expression. Induction of CREB-dependent gene expression can be achieved, for example, via up-regulation of positive effectors of CREB function and/or down- regulation of negative effectors of CREB function. Positive effectors of CREB function include adenylate cyclases and CREB activators. Negative effectors of CREB function include cAMP phosphodiesterase (cAMP PDE) and CREB repressors.
A memory agent can enhance CREB pathway function by acting biochemically upstream of or directly acting on an activator or repressor form of a CREB protein and/or on a CREB protein containing transcription complex. For example, CREB pathway function can be affected by increasing CREB protein levels transcriptionally, post-transcriptionally, or both transcriptionally and post-transcriptionally; by altering the affinity of CREB protein to other necessary components of the of the transcription complex, such as, for example, to CREB- binding protein (CBP protein); by altering the affinity of a CREB protein containing transcription complex for DNA CREB responsive elements in the promoter region; or by inducing either passive or active immunity to CREB protein isoforms. The particular mechanism by which a memory agent enhances CREB pathway function is not critical to the practice of the invention.
Memory agents can be administered directly to an animal in a variety of ways. In a specific embodiment, memory agents are administered systemically. Other routes of administration are generally known in the art and include intravenous including infusion and/or bolus injection, intracerebroventricularly, intrathecal, parenteral, mucosal, implant, intraperitoneal, oral, intradermal, transdermal (e.g., in slow release polymers), intramuscular, subcutaneous, topical, epidural, etc. routes. Other suitable routes of administration can also be used, for example, to achieve absorption through epithelial or mucocutaneous linings. Particular memory agents can also be administered by gene therapy, wherein a DNA molecule encoding a particular therapeutic protein or peptide is administered to the animal, e.g., via a vector, which causes the particular protein or peptide to be expressed and secreted at therapeutic levels in vivo.
A vector, as the term is used herein, refers to a nucleic acid vector, e.g., a DNA plasmid, virus or other suitable replicon (e.g., viral vector). Viral vectors include retrovirus, adenovirus, parvovirus (e.g., adeno-associated viruses), coronavirus, negative strand RNA viruses such as orthomyxovirus (e.g., influenza virus), rhabdovirus (e.g., rabies and vesicular stomatitis virus), paramyxovirus (e.g. measles and Sendai), positive strand RNA viruses such as picomavirus and alphavirus, and double stranded DNA viruses including adenovirus, herpesvirus (e.g., Herpes
Simplex virus types 1 and 2, Epstein-Barr virus, cytomegalovirus), and poxvirus (e.g., vaccinia, fowlpox and canarypox). Other viruses include Norwalk virus, togavirus, flavivirus, reoviruses, papovavirus, hepadnavirus, and hepatitis virus, for example. Examples of retroviruses include: avian leukosis-sarcoma, mammalian C-type, B-type viruses, D-type viruses, HTLV-BLV group, lentivirus, spumavirus (Coffin, J. M., Retroviridae: The viruses and their replication, In
Fundamental Virology, Third Edition, B. N. Fields, et al., Eds., Lippincott-Raven Publishers,
Philadelphia, 1996). Other examples include murine leukemia viruses, murine sarcoma viruses, mouse mammary tumor virus, bovine leukemia virus, feline leukemia virus, feline sarcoma virus, avian leukemia virus, human T-cell leukemia virus, baboon endogenous virus, Gibbon ape leukemia virus, Mason Pfizer monkey virus, simian immunodeficiency virus, simian sarcoma virus, Rous sarcoma virus and lentiviruses. Other examples of vectors are described, for example, in McVey et al., U.S. Pat. No. 5,801,030, the teachings of which are incorporated herein by reference.
A nucleic acid sequence encoding a protein or peptide (e.g., CREB protein, CREB analog (including CREM, ATF-1), CREB-like molecule, biologically active CREB fragment, CREB fusion protein, CREB function modulator) can be inserted into a nucleic acid vector according to methods generally known in the art (see, e.g., Ausubel et al., Eds., Current Protocols in
Molecular Biology, John Wiley & Sons, Inc., New York (1998); Sambrook et al., Eds.,
Molecular Cloning: A Laboratory Manual, 2nd edition, Cold Spring Harbor University Press,
New York (1989)).
The mode of administration is preferably at the location of the target cells. In a particular embodiment, the mode of administration is to neurons.
Memory agents can be administered together with other components of biologically inactive agents, such as pharmaceutically acceptable surfactants or carriers (e.g., glycerides), excipients (e.g., lactose), stabilizers, preservatives, humectants, emollients, antioxidants, carriers, diluents and vehicles. If desired, certain sweetening, flavoring and/or coloring agents can also be added. When combined with various inactive ingredients, a memory agent may also be referred to as a pharmaceutical composition.
Memory agents can be formulated as a solution, suspension, emulsion or lyophilized powder in association with a pharmaceutically acceptable parenteral vehicle. Examples of such vehicles are water, saline, Ringer’s solution, isotonic sodium chloride solution, dextrose solution, and 5% human serum albumin. Liposomes and nonaqueous vehicles such as fixed oils can also be used. The vehicle or lyophilized powder can contain additives that maintain isotonicity (e.g., sodium chloride, mannitol) and chemical stability (e.g., buffers and preservatives). The formulation can be sterilized by commonly used techniques. Suitable pharmaceutical carriers are described in Remington’s Pharmaceutical Sciences.
The dosage of memory agent administered to an animal is that amount required to effect a change in CREB-dependent gene expression, particularly in neurons. The dosage administered to an animal, including frequency of administration, will vary depending upon a variety of factors, including pharmacodynamic characteristics of the particular memory agent, mode and route of administration; size, age, sex, health, body weight and diet of the recipient; nature and extent of symptoms being treated or nature and extent of the memory being enhanced or modulated, kind of concurrent treatment, frequency of treatment, and the effect desired.
Memory agents can be administered in single or divided doses (e.g., a series of doses separated by intervals of days, weeks or months), or in a sustained release form, depending upon factors such as nature and extent of symptoms, kind of concurrent treatment and the effect desired. Other therapeutic protocols or agents can be used in conjunction with the present invention.
The teachings of all the articles, patents and patent applications cited herein are incorporated by reference in their entirety.
EXAMPLE 1
A study was undertaken to examine the effects of a memory agent (HT-0712).
The study was conducted using 6 aged male macaques (age approximately 22 years at onset of the study which is equivalent to approximately 66 human years) previously trained to performed certain memory tasks. Assessments of memory performance used the CANTAB system (the Cambridge Neuropsychological Test Automated Battery) and a new task.
Discrimination Learning — General Description of a Long Term Retrieval Task (DL
LTR)
In this task, animals are presented with 2 pairs of stimuli (e.g. 1 pair of shapes and 1 pair of lines) over the course of a daily test session. For each pair of stimuli, one stimulus is arbitrarily designated as the positive stimulus (i.e., touch of that stimulus is rewarded). Each pair of stimuli is presented 14 times during a daily session that consists of 28 trials. The pairs of stimuli (shapes or lines) are presented in a pseudo randomized fashion during each session.
Animals have to touch the “positive” shape or line in order to receive a sugar pellet reward accompanied by a pleasant tone. Touching the alternative shape or line results in a negative tone, no sugar pellet and a time out. Animals are tested daily until they reach a performance criterion of 85% correct responses during a daily session. When this criterion is reached, animals receive no further testing for the next 7 days. On day 8 post-criterion, animals are tested again using the same pairs of stimuli that they have seen previously learned in order to assess long term retrieval of the learned discriminations.
Drug Administration
All drugs were administered orally in marshmallow while the animal was in a specially designed testing cage. Vehicle was marshmallow alone.
The treatment schedule is shown in Table 1. Treatments were administered sequentially starting with treatment 1. Each treatment (dose of HT-0712 or vehicle) was administered once per day for 4 days before behavioral training began and then continued at 1 treatment (dose of
HT-0712 or vehicle) per day, delivered four hours before testing, for the duration of the training period. When each individual animal reached performance criterion of at least 85% correct responses during a daily session, training and dosing ceased for seven days. Then, on post- criterion day 8, animals were tested again on the DL. LTR task (retention testing).
A second vehicle study was conducted at the end of the drug trials using the first 3 animals that completed the 100mg/kg dosing study.
Table 1 — Treatment Schedule elo pp 1 2(N=¢6) HT-0712 mg/kg
HT-0712 10 3(N=6) mg/kg 100 4(N=6) HT-0712 mg/kg oe oe
Analysis of Behavioral Data
The percent correct responses on the total number of daily trials were recorded as well as the number of days needed to reach the criterion (at least 85% correct responses in a single test session). The percent correct responses on the retention trial was recorded for the entire retention trial session and sub-analyzed for performance differences on trials 1-14 versus trials 15-28.
Data from vehicle trials were compared to data from drug trials using a one way
ANOVA. Post hoc comparisons were made using the Bonferroni t-test.
Results
There were no noticeable behavioral or physical side effects following administration of
HT-0712 at any dose given during the study. Five of the six animals used displayed improved memory performance as evidenced by a decrease in the number of days needed to reach criterion. One animal (0ld-9) did not show improved task performance at any dose of HT-0712 administered. Data from this non-responder were removed from the statistical analysis.
Vehicle Treatment
During the first vehicle study, all animals reached criterion over a period of 26.3 + 4.6 days. The mean criterion value reached was 89.3 + 1.8% correct responses. Mean performance at the retention trial was of 79.7 + 5.9% correct responses. When retention trial performance was divided between trials 1 to 14 versus trials 15 to 28, animals performed 77.5 +5.1% correct responses and 82.3 + 7.5% correct responses, respectively.
The second (post drug study) vehicle study was performed using the first 3 animals that finished the drug trials. During this second vehicle study, animals reached criterion over a period of 20.0 + 4.5 days. Their mean criterion value was 86.3 + 1.3% correct responses.
Performance at the retention trials averaged 64.0 + 4.0% correct responses. When retention trial performance was divided between trials 1 to 14 versus trials 15 to 28, animals performed 59.3 + 8.4% correct responses and 69.0 + 10.4% correct responses, respectively.
No statistically significant differences were found between the results of the pre-study and post-study vehicle trials (t= 1.168, (P = 0.363)).
Memory Agent Treatment
At the lowest dose of HT-0712 used in this study (1 mg/kg), animals reached criterion over a period of 12.0 + 3.6 days, at a performance level of 91.4 + 1.8% correct responses). The mean performance of the animals at the retention trial was of 85.8 + 4.6% correct responses.
When retention trial performance was divided between trials 1 to 14 versus trials 15 to 28, animals performed at a level of 80.2 + 6.2% correct responses and 91.6 + 3.4% correct responses, respectively.
At the medium dose of HT-0712 used in the study (10mg/kg), animals reached criterion (90.0 + 2.6% correct responses) over a period of 11.8 + 2.3 days. The mean performance of these animals at retention testing was of 79.2 + 3.5% correct responses. When retention test performance was divided between trials 1 to 14 versus trials 15 to 28, animals performed at a level of 71.4 + 3.4% correct and 87.2 + 4.8% correct, respectively.
At the highest dose of HT-0712 used (100mg/kg), animals reached criterion (86.4 + 0.7% correct responses) over a period of 9.0 + 2.8 days. The mean performance of these animals at retention testing was of 65.0 + 3.5% correct responses. When retention test performance was divided between trials 1 to 14 versus trials 15 to 28, animals performed at a level of 58.4 + 4.1% correct and 71.4 + 6.1% correct, respectively.
The effect of treatment on days to criterion was significant (repeated measures ANOVA,
F(4,3) = 6.327, p= 0.008). Post hoc comparisons using the Bonferroni t-test showed a significant difference between vehicle and each dose of HT-0712 (p < 0.050 for each comparison).
There was no significant effect of treatment on the level of performance attained on the criterion day (F(4,3) = 1.408, p = 0.289).
There was no significant effect of treatment on the level of performance attained at the retention test (F(4,3) = 3.199, p= 0.062). Analysis of treatment effect on retention trial performance at trials 1-14 and trials 15-28, also failed to reach statistical significance (p = 0.058 and p = 0.167, respectively).
This study was conducted using a new task, the Discrimination Learning — Long Term
Retrieval task (DL LTR), that was designed to assess the effects of an experimental memory agent on learning and retention in aged non human primates.
The results of the vehicle control studies indicate that normal aged animals require a long time (ex. > 20 days) to reach an 85% correct response criterion on this test. Additionally, the post-drug vehicle test results indicate that the increase in performance seen with HT-0712 was not due to an increase in the animal’s proficiency in the test or a practice effect as the second vehicle control test results were not significantly different from the results of the first vehicle study.
Five of the six animals tested showed improved performance following administration of
HT-0712. The improvement was expressed as a significant decrease in the number of days to reach criterion, showing improved learning abilities when treated with HT-0712.
The response of the animals could be separated into 2 general groups. In the first group (animals old-5 and old-8), the best dose for improving performance was the 1mg/kg dose of HT- 0712. These animals showed a decrement in performance as the dose administered increased from 1 to 10 to 100mg/kg. That is, with increasing doses of HT-0712, it took longer for the animals to reach criterion (i.e., 4, 5, and 10 days to criterion (old-5) and 3, 12, and 18 days to criterion for (old-8) after administration of 1, 10, or 100 mg/kg, respectively). The second group of animals (old-1, old-2 and old-7) showed a more typical dose-response effect in which performance improved with increasing doses (21, 15, and 3 days to criterion; 17, 18, and 11 days to criterion, and 15, 9, and 3 days to criterion for old-1, old2 and old-7 respectively with doses of 1, 10, and 100 mg/kg).
The present animals were previously tested and assessed for cognitive deficits using both delayed matching to sample (DMTS) and paired associative learning (PAL) tasks. These animals were ranked accordingly to their level of performance on these tasks (i.e., animals were ranked per task from 1 to 6, 1 being the best performer and 6 the worst (see Table 10). This ranking showed that the animal that did not respond to HT-0712 was ranked 1 on performance of the
PAL and 2 on performance of the DMTS. This same animal also had the best performance on the first vehicle study performed on the current project.
In summary, the results of this study show that HT-0712 significantly improves the learning ability and long term memory of normal aged non-human primates using particular systems and methods of the present invention.
Tables
Table 2: Descriptive statistics for the entire study group, including NHP old-9
Me RS
Deviation Error to C valve retention test 14 15-28 to C value retention test 1-14 15-28 0
C retention test 14 28
C value retention test 14 15-28 to C value retention test 100 mg RT 59.333 8.477 3.461 nest oe
EE
Legends: C: criterion; RT: retention test, RT 1-14 Retention test trials 1 to 14; RT 15-28: retention test trials 15 to 28
Table 3: Descriptive statistics for the entire study group, excluding NHP old-9
Mean | Criterion day to C value retention test
Vehiclel 77.200 13.936 we | nee value
Vehicle2 64.000 9.899 emtemes | _0
RT 1-14
C ie retention test 14 15-28 to C i:
i240 10 mg RT 87.200 10.756 4.810 15-28 100 mg day 9.000 6.285 2.811 toC 100 mg C 86.400 1.517 0.678 value 100 mg 65.000 7.842 3.507 retention test 100 mg RT 58.400 9.127 4.082 1-14 100 mg RT 71.400 13.631 6.096 15-28
Legends: C: criterion; RT: retention test, RT 1-14 Retention test trials 1 to 14; RT 15-28: retention test trials 15 to 28
Raw data per treatment
Table 4: Vehicle 1 [Treatment |DaystoC | Cvalue [RT overall |RT trials 1-14 | RT trials 15-28
Old-1 | Vehicle 1 86.00 57.00 50.00 0
Old-2 | Vehicle 1 86.00 79.00 100.00 0
Old-5 | Vehicle 1 96.00 93.00 100.00 0
Old-7 | Vehicle 1 86.00 86.00 79.00 0
Old-8 | Vehicle 1 89.00 71.00 79.00 0
Old-9 | Vehicle 1 93.00 79.00 86.00 0
Table 5: 1mg/kg HT-0712
Troan Paysio€ Cale RT overall RT trials 1- | RT trials 15-28 14
Old-1 1 21 86.00 93.00 93.00 93.00 mg/kg 0Ol1d-2 1 17 93.00 86.00 79.00 93.00 mg/kg _81-
Old-5 1 4 8 93.00 86.00 100.00 mg/kg 9.00
Old-7 1 15 9 68.00 57.00 79.00 mg/kg 3.00
Old-8 1 3 9 89.00 86.00 93.00 mg/kg 6.00 0ld-9 1 16 8 68.00 64.00 71.00 mg/kg 9.00
Table 6: 10mg/kg HT-0712
Treament [Days Cae RT overall | RT trials 1-14 | RT trials 15-28 to C
Old-1 | 10 mg/kg 86.00 75.00 64.00 86.00
Old-2 [10 mg/kg 86.00 71.00 71.00 71.00
Old-5 | 10 mg/kg 100.00 86.00 79.00 93.00
Old-7 [10mg/kg | 9 [89.00 75.00 64.00 86.00
Old-8 | 10 mg/kg 89.00 89.00 79.00 100.00
Old-9 | 10 mg/kg 86.00 86.00 86.00 86.00
Table 7: 100mg/kg HT-0712 e (Pas Crab RT overall | RT trials 1-14 | RT trials 15-28 to C
Old-1 100 mg/kg 89.00 57.00 50.00 64.00
Old-2 100 mg/kg 86.00 68.00 50.00 86.00 0ld-5 100 mg/kg 86.00 57.00 57.00 57.00
Old-7 100 mg/kg 86.00 68.00 71.00 64.00
Old-8 100 mg/kg 85.00 75.00 64.00 86.00 01d-9 100 mg/kg 86.00 71.00 64.00 79.00
Table 8: Vehicle 2
Treatment |DaystoC |Cvalue [RT overall [RT trials 1-14 | RT trials 15-28
Old-1 Vehicle 2 85.00 71.00 71.00 71.00 0ld-5 Vehicle 2 85.00 57.00 64.00 50.00 01d-9 Vehicle 2 89.00 64.00 43.00 86.00
Legends: C: criterion; RT: retention test, RT 1-14 Retention test trials 1 to 14; RT 15-28: retention test trials 15 to 28
Table 9: Description of animals used in the study
ID Weight at start of Estimated age Sex study
Old-1 9.9 kg 22 years old 0ld-2 9.65 kg 22 years old
Old-5 22 years old 0ld-7 10.6 kg 22 years old
Old-8 22 years old 01d-9 11.15 kg 22 years old
Table 10: Ranking of animals used in the study on PAL and DMTS odl]| old2] old5] old7] old8| old9
PAL | 5p ef 2] 0 3] 1
DM
TS 1 5 4 3 2 meanrank| | 3] ss[ 0 3] 3] LS]
Rankings were calculated for PAL and DMTS task as follows: 1. PAL: Mean number of trials needed to complete the most difficult level of the task (3 stimuli / 3 locations). 2. DMTS: Mean number of correct response at the longer delay.
Animals were ranked per task from 1 to 6, 1 being the best performer and 6 the worst.
EXAMPLE 2: SINGLE-BLIND STUDY IN HEALTHY, ELDERLY, HUMAN
SUBJECTS
Study Design
The study using the general protocol and drug administration as set forth in Example 1 can be performed using humans. As described below, a long term retrieval task can utilize stimuli in the form of face — name and/or occupation pairings. The human subjects can be shown a picture of a face along with the name and/or occupation of a person. An occupation may be listed for each name-face pair. During encoding, the human subject is asked to decide if the name fits with the occupation. During the test, the human subject is shown intact, rearranged, and novel face-name pairs (presented without the occupation) and asked to decide if the face and name pairings are intact, rearranged, or novel. Using this testing, human subjects can then be evaluated in a manner as set forth in Example 1.
In one embodiment, a single site, double-blind, three-way cross-over study was performed that tested the following three dosing regimens: (1) HT-0712 45 mg po for 7 days; (2) HT-0712 45 mg po plus warfarin 2.5 mg po for 7 days; and (3) Warfarin 2.5 mg po for 7 days. There was a seven-day washout periods between dosing periods. Subjects remained in- house for three (72 hours) of the seven days washout days, for study related procedures.
Subjects were furloughed from the clinic for four of the seven washout days. With regard to subject selection criteria, there were no inclusion and/or exclusion criteria for the paired associate test.
Study Schedule
Group I subjects received 45 mg doses of HT-0712 on Days 1,2,3,4,5,6, and 7; 45 mg doses of HT-0712 plus 2.5 mg doses of warfarin on Days, 15, 16, 17, 18, 19, 20, and 21; and 2.5 mg doses of warfarin on Days 29, 30, 31, 32,33, 34, and 35. Group II subjects received 45 mg doses of HT-0712 plus 2.5 mg doses of warfarin on Days 1,2,3,4,5,6, and 7; 2.5 mg doses of warfarin on Days 15, 16, 17, 18, 19, 20, and 21; and 45 mg doses of HT-0712 on Days 29, 30, 31, 32,33, 34, and 35. Group III subjects received 2.5 mg doses of warfarin on Days 1, 2,3,4,5,6, and 7; 45 mg doses of HT-0712 on Days 15, 16, 17, 18, 19, 20, and 21; and 45 mg doses of
HT-0712 plus 2.5 mg doses of warfarin on Days 29, 30, 31, 32, 33, 34, and 35.
Table 11: Unblinded Subject Codes 0 0 0 02 01 03 0 0 05 04 0 0 08 07 0 0 0 12 11 10 0 0 0 13 14 0 0 0 16 18 17 0 0 0 19 20 21
Paired Associates Testing
Materials: Materials consisted of 21 Lenovo notebook computers. Each notebook was configured to eliminate all auto-configuration software and reduce settings which might interfere with the internal clock settings and E-Run software. E-Run (v1.2.1.68) was installed on all the notebook computers to administer the paired associate test. 120 grayscale faces (male and female) were paired with a two-word professions, such as “fire fighter.” Grayscale face images were drawn from a face database from Lund University Cognitive Science Lab. Only two-word or compound-word professions were used. The 120 face-name pairs were divided into three groups of 40. During each round the same 40 face-name pairs were used throughout the round.
Procedure - Timing of Administration: Memory testing commenced approximately 6 hours post-drug administration. All memory testing was completed prior to daily blood samples being taken. The training was performed in three Rounds (or Segments) consisting of 14 days as shown in Table 12. The testing was performed over 42 days. In a given round on day 1,
Subjects were familiarized with the computers and trained how to use the test software. On day 2 subjects were given an encoding and retrieval session. On days 3-7, subjects were tested daily for recall. On day 10 subjects were tested on half the face-name pairs, and on day 14, subjects were tested on the remaining half of the face-name pairs followed by a complete test of all face- name pairs used in that round.
Table 12: Training and Testing tom [2 | 0 fe fe fe fr sf yw 1 Day
Procedu |TrailEncodi Testing | Testing | Testing | Testing | Testin Testin Testin re hing ne g g g g g g g # of 40 | 40 | 40 | 40 | 40 | 40 Pairs tant I
Pairs Pairs | Pairs | Pairs | Pairs | Pairs | Pairs 1-20 21-40:
Part II:
Repeat all 40 Pairs
Testing Procedure Familiarization: On day 1, subjects were familiarized with the computers and trained how to use the test software by receiving a mock encoding and retrieval session consisting of nine face-name pairs. These pairs were never observed again.
Encoding and Retrieval: On Day 2, each participant received a single encoding and retrieval session:
Encoding: During the encoding session, participants see 40 faces paired with professions one at a time on a computer screen. For instance they see a face, and to the right, the profession “ice skater.” Their task for each face-profession pair is to form a vivid mental image in which the person pictured is carrying out the profession appearing to the right. Thus, for a face paired with ice skater, they might imagine that person doing a difficult jump and falling, or imagine them very happy because they’ve won the gold medal. After 5 seconds of viewing the face profession pair, they were prompted to rate how easy it was to form the mental image on a scale of 1-3: 1 if it was easy, 2 if it was difficult, 3 if they were unsuccessful at creating a mental image. After 2 seconds, the next face profession pair was displayed.
Retrieval: In this part of the experiment, participants were administered a cued-recall test for the 40 face-profession pairs they had seen in during Encoding. During the retrieval test subjects were presented face without the associated profession. Next to the face there was a box for them to type in the profession that was paired with that face during encoding. Once the participant types a response, they received feedback as to whether the profession they typed was correct or incorrect. If the response was correct, “Correct!” appeared on the screen with the appropriate face and profession pairing, followed by the next stimulus pair. If it was incorrect, the correct face and profession pairing was presented as feedback on the screen for three seconds, prior to the presentation of the next stimulus pair. The session ended once all forty face-profession pairs were presented. This retrieval session was presented once, each day 3-7, of the study.
Long-term memory assessment: Three days after each final drug dose and prior to being discharged (day 10, 24, and 38) participants were administered a cued-recall test consisting of 20 face-profession pairs to measure long term stability of the face-profession memories. Seven days after each drug treatment (dayl4 and 28, and 42), participants were administered the remaining face-profession pairs which were not previously tested. On days 14 and 28, and 42, a minute rest period followed the presentation of the 20 face-profession pairs. Following this one minute 20 of rest, participants were administered the complete set of 40 face-profession pairs.
Results: Data reflecting participant recall was collected and graphed as shown in Figure 5. These data show that long-lasting memory of a paired-associate task can be established with sufficient daily repetitions of training.
Blinding Procedure: The study was a double-blind placebo controlled trial. The pharmacist had responsibility for maintaining subject treatment codes.
Thus, it is seen that various methods are provided. One skilled in the art will appreciate that the present invention can be practiced by other than the various embodiments and preferred embodiments, which are presented in this description for purposes of illustration and not of limitation, and the present invention is limited only by the claims that follow. It is noted that equivalents for the particular embodiments discussed in this description may practice the invention as well.
While various embodiments of the present invention have been described above, it should be understood that they have been presented by way of example only, and not of limitation.
Likewise, the various figures may depict an example configuration for the invention, which is done to aid in understanding the features and functionality that may be included in the invention.
The invention is not restricted to the illustrated example configurations, but the desired features may be implemented using a variety of alternative configurations. Indeed, it will be apparent to one of skill in the art how alternative functional, logical or physical configurations may be implemented to implement the desired features of the present invention. Additionally, with regard to method claims, the order in which the steps are presented herein shall not mandate that various embodiments be implemented to perform the recited functionality in the same order unless the context dictates otherwise.
Although the invention is described above in terms of various exemplary embodiments and implementations, it should be understood that the various features, aspects and functionality described in one or more of the individual embodiments are not limited in their applicability to the particular embodiment with which they are described, but instead may be applied, alone or in various combinations, to one or more of the other embodiments of the invention, whether or not such embodiments are described and whether or not such features are presented as being a part of a described embodiment. Thus the breadth and scope of the present invention should not be limited by any of the above-described exemplary embodiments.
Terms and phrases used in this document, and variations thereof, unless otherwise expressly stated, should be construed as open ended as opposed to limiting. As examples of the foregoing: the term “including” should be read as meaning “including, without limitation” or the like; the term “example” is used to provide exemplary instances of the item in discussion, not an exhaustive or limiting list thereof; the terms “a” or “an” should be read as meaning “at least one,” “one or more” or the like; and adjectives such as “conventional,” “traditional,” “normal,” “criterion,” “known” and terms of similar meaning should not be construed as limiting the item described to a given time period or to an item available as of a given time, but instead should be read to encompass conventional, traditional, normal, or criterion technologies that may be available or known now or at any time in the future. Likewise, where this document refers to technologies that would be apparent or known to one of ordinary skill in the art, such technologies encompass those apparent or known to the skilled artisan now or at any time in the future.
A group of items linked with the conjunction “and” should not be read as requiring that each and every one of those items be present in the grouping, but rather should be read as
“and/or” unless expressly stated otherwise. Similarly, a group of items linked with the conjunction “or” should not be read as requiring mutual exclusivity among that group, but rather should also be read as “and/or” unless expressly stated otherwise. Furthermore, although items, elements or components of the invention may be described or claimed in the singular, the plural is contemplated to be within the scope thereof unless limitation to the singular is explicitly stated.
The presence of broadening words and phrases such as “one or more,” “at least,” “but not limited to” or other like phrases in some instances shall not be read to mean that the narrower case is intended or required in instances where such broadening phrases may be absent. As will become apparent to one of ordinary skill in the art after reading this document, the illustrated embodiments and their various alternatives may be implemented without confinement to the illustrated examples.
Claims (145)
1. A method comprising the steps of: assessing the effectiveness of a memory agent administered to a subject, wherein said assessing comprises presenting to said subject sets of stimuli; and evaluating said subject’s response to said stimuli.
2. The method of claim 1, wherein said stimuli affect a CREB pathway.
3. The method of claim 2, wherein said stimuli affect the subject's long term memory.
4. The method of claim 1, wherein said assessing further comprises selecting a performance criterion and evaluating the number of days of training required for the subject to reach the performance criterion.
5. The method of claim 1 wherein said sets of stimuli comprise a plurality of pairs of stimuli.
6. The method of claim 5 wherein each of said plurality of pairs of stimuli comprises an element that has an identifiable association with the other element of said pair.
1. The method of claim 6 wherein said identifiable association is selected from the group consisting of a face — name association and a word — word association.
8. The method of claim 1 wherein said subject is an animal.
9. The method of claim 8 wherein said animal is a mammal.
10. The method of claim 9 wherein said mammal is selected from the group consisting of a primate, a mouse and a rat.
11. The method of claim 10 wherein said primate is selected from the group consisting of a human, a monkey, a lemur, a macaque and an ape.
12. The method of claim 11 wherein said primate is a human.
13. The method of claim 1 wherein said subject is a plurality of subjects.
14. The method of claim 13 wherein said plurality of subjects comprises a control group and an experimental group.
15. The method of claim 14 wherein said assessing comprises comparing said control group to said experimental group.
16. The method of claim 1, wherein said memory agent is one or more selected from the group consisting of a compound having the structure: Tals 4 wherein each of Yi, Y,, Y3, and Yy is independently --H; straight chained or branched C;-C; alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C,-C; alkenyl or alkynyl; Cs-C7 cycloalkyl or Cs-C7 cycloalkenyl; --F, --Cl1, --Br, or --1; --NO»; --N3; --CN; --ORy, --SRy4, --OCORy, --CORy, --NCORy, --N(R4)2, --CON(R4)2, or --COORy; aryl or heteroaryl; or any two of Yi, Y2, Y3 and Y4 present on adjacent carbon atoms can constitute a methylenedioxy group; wherein each Ry is independently --H; straight chained or branched C;-C; alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C,-C7 alkenyl or alkynyl; Cs- C7 cycloalkyl, Cs-C7 cycloalkenyl, aryl or aryl(C-Cg)alkyl; wherein A is A’, straight chained or branched C;-C7 alkyl, aryl, heteroaryl, aryl(C;-Cg)alkyl or heteroaryl(C;-Ce)alkyl; wherein A' is
%, ~~ Poa el bye ER, wherein R; and R; are each independently H, straight chained or branched C;-C; alkyl, -F, --C, - -Br, --1, --NO,, or --CN; wherein Rj is H, straight chained or branched C;-C7 alkyl, --F, --Cl, -- Br, --1, --NO,, --CN, --OReg, aryl or heteroaryl; wherein Rs is straight chained or branched C;-C; alkyl, --N(R4)2, --OR4 or aryl; wherein Rg is straight chained or branched C;-C5 alkyl or aryl; wherein B is aryl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, indolizinyl, indol-4-yl, indo1-5-yl, indol-6-yl, indol-7-yl, isoindolyl, benzo[b]furan-4-yl, benzo[b]furan-5-yl, benzo[b]furan-6-yl, benzo[b]furan-7-yl, benzo[b]thiophen-4-yl, benzo[b]thiophen-5-yl, benzo[b]thiophen-6-yl, benzo[b]thiophen-7-yl, indazolyl, benzimidazolyl, benzo[b]thiazolyl, purinyl, imidazo[2,1-b]thiazolyl, quinolinyl, isoquinolinyl, quinazolinyl, 2,1,3-benzothiazolyl, furanyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, triazolyl, thiadiazolyl, benzoxazolyl, benzisoxazolyl, cinnolinyl, quinoxalinyl, 1,8- napthyridinyl, pteridinyl, or phthalimidyl; provided however, that the carbon atom or carbon atoms ortho to the nitrogen atom of the imine bond may only be substituted with one or more of the following --F, -Cl, --Br, --1, --CN, methyl, ethyl or methoxy; wherein n is an integer from 1 to 4 inclusive; wherein aryl is phenyl or napthyl, including phenyl and napthyl substituted with one or more of the following: -F, -Cl, -Br, -I, -NO,, -CN, straight chained or branched C;-C;
alkyl, straight chained or branched C;-C7; monofluoroalkyl, straight chained or branched C;-C polyfluoroalkyl, straight chained or branched C,-C7 alkenyl, straight chained or branched C,-C7 alkynyl, Cs-C; cycloalkyl, C;-C7 monofluorocycloalkyl, Cs-C7 polyfluorocycloalkyl, Cs-Cy cycloalkenyl, -OR4, SRy4, -OCORy, -COR4, -NCORy, -COzR4, -CON(R4); or (CH3),-O- (CH;)nCHs; or a pharmaceutically acceptable salt thereof.
17. The method of claim 1, wherein said memory agent is one or more selected from the group consisting of a compound having the structure: CF, CF, N / N OH or O (> NH CH; OcPent OMe wherein Me is methyl, cPent is cyclopentyl and the 3 and 5 carbons are in the S configuration.
18. A method comprising the steps of assessing the effectiveness of a memory agent administered to a subject, wherein said assessing comprises selecting a performance criterion, training the subject by presenting the subject with sets of stimuli, evaluating the subject's response to the stimuli to determine whether the subject has reached the performance criterion, and determining the number of days of training required to reach the performance criterion.
19. The method of claim 18 wherein said sets of stimuli comprise a plurality of pairs of stimuli.
20. The method of claim 19 wherein each of said plurality of pairs of stimuli comprises an element that has an identifiable association with the other element of said pair.
21. The method of claim 20 wherein said identifiable association is selected from the group consisting of a face — name association and a word — word association.
22. The method of claim 18 wherein said stimuli affect a CREB pathway.
23. The method of claim 18 wherein said stimuli affect the subject's long term memory.
24. The method of claim 18 wherein the performance criterion is a percentage representing the quality of the subject's response to the stimuli.
25. The method of claim 18, wherein the performance criteria represents the subject's acquisition of long term memory.
26. The method of claim 18 wherein said subject is an animal.
27. The method of claim 26 wherein said animal is a mammal.
28. The method of claim 27 wherein said mammal is selected from the group consisting of a primate, a mouse and a rat.
29. The method of claim 28 wherein said primate is selected from the group consisting of a human, a monkey, a lemur, a macaque and an ape.
30. The method of claim 29 wherein said primate is a human.
31. The method of claim 18 wherein said subject is a plurality of subjects.
32. The method of claim 31 wherein said plurality of subjects comprises a control group and an experimental group.
33. The method of claim 32 wherein said assessing comprises comparing said control group to said experimental group.
34. The method of claim 18, wherein said , memory agent is one or more selected from the group consisting of a compound having the structure: $ yo vp T \ wherein each of Yi, Y», Y3, and Y4 is independently --H; straight chained or branched C;-C; alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C,-C7 alkenyl or alkynyl; C;3-C5 cycloalkyl or Cs-C7 cycloalkenyl; --F, --Cl, --Br, or --I; --NOy; --N3; --CN; --ORy, --SRy, --OCORy, --CORy, --NCORy, --N(Ry)2, --CON(Ry),, or --COORy; aryl or heteroaryl; or any two of Yy, Y,, Y3 and Y, present on adjacent carbon atoms can constitute a methylenedioxy group; wherein each Ry is independently --H; straight chained or branched C;-C7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C,-C7 alkenyl or alkynyl; Cs- C7 cycloalkyl, Cs-C7 cycloalkenyl, aryl or aryl(C-Cg)alkyl; wherein A is A’, straight chained or branched C;-C5 alkyl, aryl, heteroaryl, aryl(C;-Cg)alkyl or heteroaryl(C;-Cg)alkyl; wherein A' is
%, ~~ Poa el bye ER, wherein R; and R; are each independently H, straight chained or branched C;-C; alkyl, -F, --C, - -Br, --1, --NO,, or --CN; wherein Rj is H, straight chained or branched C;-C7 alkyl, --F, --Cl, -- Br, --1, --NO,, --CN, --OReg, aryl or heteroaryl; wherein Rs is straight chained or branched C;-C; alkyl, --N(R4)2, --OR4 or aryl; wherein Rg is straight chained or branched C;-C5 alkyl or aryl; wherein B is aryl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, indolizinyl, indol-4-yl, indo1-5-yl, indol-6-yl, indol-7-yl, isoindolyl, benzo[b]furan-4-yl, benzo[b]furan-5-yl, benzo[b]furan-6-yl, benzo[b]furan-7-yl, benzo[b]thiophen-4-yl, benzo[b]thiophen-5-yl, benzo[b]thiophen-6-yl, benzo[b]thiophen-7-yl, indazolyl, benzimidazolyl, benzo[b]thiazolyl, purinyl, imidazo[2,1-b]thiazolyl, quinolinyl, isoquinolinyl, quinazolinyl, 2,1,3-benzothiazolyl, furanyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, triazolyl, thiadiazolyl, benzoxazolyl, benzisoxazolyl, cinnolinyl, quinoxalinyl, 1,8- napthyridinyl, pteridinyl, or phthalimidyl; provided however, that the carbon atom or carbon atoms ortho to the nitrogen atom of the imine bond may only be substituted with one or more of the following --F, -Cl, --Br, --1, --CN, methyl, ethyl or methoxy; wherein n is an integer from 1 to 4 inclusive; wherein aryl is phenyl or napthyl, including phenyl and napthyl substituted with one or more of the following: -F, -Cl, -Br, -I, -NO,, -CN, straight chained or branched C;-C;
alkyl, straight chained or branched C;-C7; monofluoroalkyl, straight chained or branched C;-C polyfluoroalkyl, straight chained or branched C,-C7 alkenyl, straight chained or branched C,-C7 alkynyl, Cs-C; cycloalkyl, C;-C7 monofluorocycloalkyl, Cs-C7 polyfluorocycloalkyl, Cs-Cy cycloalkenyl, -OR4, SRy4, -OCORy, -COR4, -NCORy, -COzR4, -CON(R4); or (CH3),-O- (CH;)nCHs; or a pharmaceutically acceptable salt thereof.
35. The method of claim 18, wherein said memory agent is one or more selected from the group consisting of a compound having the structure: CF, CF, N / N OH or O (> NH CH; OcPent OMe wherein Me is methyl, cPent is cyclopentyl and the 3 and 5 carbons are in the S configuration.
36. A method comprising the steps of assessing the effectiveness of a memory agent administered to a subject, wherein said assessing comprises selecting a performance criterion, training the subject by presenting the subject with sets of stimuli, evaluating the subject's response to said stimuli to determine whether the subject has reached the performance criterion, repeating said presenting and evaluating until the subject reaches the performance criterion, and determining the number of days of training required for the subject to reach the performance criterion.
37. The method of claim 36, wherein said stimuli affect a CREB pathway.
38. The method of claim 36, wherein said stimuli affect the subject's long term memory.
39. The method of claim 36 wherein said sets of stimuli comprise a plurality of pairs of stimuli.
40. The method of claim 39 wherein each of said plurality of pairs of stimuli comprises a element that has an identifiable association with the other element of said pair.
41. The method of claim 40 wherein said identifiable association is selected from the group consisting of a face — name association and a word — word association.
42. The method of claim 36 wherein said subject is an animal.
43. The method of claim 42 wherein said animal is a mammal.
44. The method of claim 43 wherein said mammal is selected from the group consisting of a primate, a mouse and a rat.
45. The method of claim 44 wherein said primate is selected from the group consisting of a human, a monkey, a lemur, a macaque and an ape.
46. The method of claim 45 wherein said primate is a human.
47. The method of claim 36 wherein said subject is a plurality of subjects.
48. The method of claim 47 wherein said plurality of subjects comprises a control group and an experimental group.
49. The method of claim 48 wherein said assessing comprises comparing said control group to said experimental group.
50. The method of claim 36, wherein said memory agent is one or more selected from the group consisting of a compound having the structure: Ir we ng TY Lo wherein each of Yi, Y», Y3, and Y4 is independently --H; straight chained or branched C;-C; alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C,-C; alkenyl or alkynyl; C;-C7 cycloalkyl or Cs-C; cycloalkenyl; --F, --Cl1, --Br, or --1; --NO»; --N3; --CN; --ORy, --SRy4, --OCORy, --CORy, --NCORy, --N(R4)2, --CON(R4)2, or --COORy; aryl or heteroaryl; or any two of Yi, Y2, Y3 and Y4 present on adjacent carbon atoms can constitute a methylenedioxy group; wherein each Ry is independently --H; straight chained or branched C;-C7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C,-C7 alkenyl or alkynyl; Cs- C7 cycloalkyl, Cs-C7 cycloalkenyl, aryl or aryl(C;-Cg)alkyl; wherein A is A’, straight chained or branched C;-C7 alkyl, aryl, heteroaryl, aryl(C;-Cg)alkyl or heteroaryl(C;-Ce)alkyl; wherein A' is
“. 1 ; F ~L A Ls LR CA Ru Sv, ‘. PAY eed bee RRR, wherein R; and R; are each independently H, straight chained or branched C;-C5 alkyl, -F, --Cl, - -Br, --1, --NO,, or --CN; wherein Rj is H, straight chained or branched C;-C7 alkyl, --F, --Cl, -- Br, --1, --NO,, --CN, --ORg, aryl or heteroaryl; wherein Rs is straight chained or branched C;-C; alkyl, --N(R4)2, --OR4 or aryl; wherein Rg is straight chained or branched C;-C5 alkyl or aryl; wherein B is aryl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, indolizinyl, indol-4-yl, indo1-5-yl, indol-6-yl, indol-7-yl, isoindolyl, benzo[b]furan-4-yl, benzo[b]furan-5-yl, benzo[b]furan-6-yl, benzo[b]furan-7-yl, benzo[b]thiophen-4-yl, benzo[b]thiophen-5-yl, benzo[b]thiophen-6-yl, benzo[b]thiophen-7-yl, indazolyl, benzimidazolyl, benzo[b]thiazolyl, purinyl, imidazo[2,1-b]thiazolyl, quinolinyl, isoquinolinyl, quinazolinyl, 2,1,3-benzothiazolyl, furanyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, triazolyl, thiadiazolyl, benzoxazolyl, benzisoxazolyl, cinnolinyl, quinoxalinyl, 1,8- napthyridinyl, pteridinyl, or phthalimidyl; provided however, that the carbon atom or carbon atoms ortho to the nitrogen atom of the imine bond may only be substituted with one or more of the following --F, -Cl, --Br, --1, --CN, methyl, ethyl or methoxy; wherein n is an integer from 1 to 4 inclusive; wherein aryl is phenyl or napthyl, including phenyl and napthyl substituted with one or more of the following: -F, -Cl, -Br, -I, -NO,, -CN, straight chained or branched C;-C7 alkyl, straight chained or branched C;-C7; monofluoroalkyl, straight chained or branched C;-C polyfluoroalkyl, straight chained or branched C,-C7 alkenyl, straight chained or branched C,-C7 alkynyl, Cs-C; cycloalkyl, C;-C7 monofluorocycloalkyl, Cs-C7 polyfluorocycloalkyl, Cs-Cy cycloalkenyl, -OR4, SRy4, -OCORy, -COR4, -NCORy, -COzR4, -CON(R4); or (CH3),-O- (CH;)mCHs; or a pharmaceutically acceptable salt thereof.
51. The method of claim 36 wherein said memory agent is one or more selected from the group consisting of a compound having the structure: CF, CF, N / N Oo ® NH CH; OcPent OMe wherein Me is methyl, cPent is cyclopentyl and the 3 and 5 carbons are in the S configuration.
52. A method comprising selecting a memory agent as a drug candidate, wherein said selecting comprises the steps of assessing said memory agent by administering said memory agent to a subject; and presenting to said subject sets of stimuli and evaluating said subject’s response to said stimuli.
53. The method of claim 52 wherein said sets of stimuli comprise a plurality of pairs of stimuli.
54. The method of claim 53 wherein each of said plurality of pairs of stimuli comprises an element that has an identifiable association with the other element of said pair.
55. The method of claim 54 wherein said identifiable association is selected from the group consisting of a face — name association and a word — word association.
56. The method of claim 52 wherein said stimuli affect a CREB pathway.
57. The method of claim 52 wherein said stimuli affect the subject's long term memory.
58. The method of claim 52, wherein said assessing further comprises selecting a performance criterion, and said evaluating comprises determining the quantity of stimuli required for the subject to reach the performance criterion.
59. The method of claim 58, wherein the performance criterion is a percentage representing the quality of the subject's response to the stimuli.
60. The method of 59, wherein the performance criteria represents the subject's acquisition of long term memory.
61. The method of claim 52 wherein said subject is an animal.
62. The method of claim 61 wherein said animal is a mammal.
63. The method of claim 62 wherein said mammal is selected from the group consisting of a primate, a mouse and a rat.
64. The method of claim 63 wherein said primate is selected from the group consisting of a human, a monkey, a lemur, a macaque and an ape.
65. The method of claim 64 wherein said primate is a human.
66. The method of claim 52 wherein said subject is a plurality of subjects.
67. The method of claim 66 wherein said plurality of subjects comprises a control group and an experimental group.
68. The method of claim 67 wherein said assessing comprises comparing said control group to said experimental group.
69. The method of claim 52, wherein said ,memory agent is one or more selected from the group consisting of a compound having the structure: $ vp T \ wherein each of Yi, Y», Y3, and Y4 is independently --H; straight chained or branched C;-C; alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C,-C7 alkenyl or alkynyl; C;3-C5 cycloalkyl or Cs-C7 cycloalkenyl; --F, --Cl, --Br, or --I; --NOy; --N3; --CN; --ORy, --SRy, --OCORy, --CORy, --NCORy, --N(Ry)2, --CON(Ry),, or --COORy; aryl or heteroaryl; or any two of Yy, Y,, Y3 and Y, present on adjacent carbon atoms can constitute a methylenedioxy group; wherein each Ry is independently --H; straight chained or branched C;-C7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C,-C7 alkenyl or alkynyl; Cs- C7 cycloalkyl, Cs-C7 cycloalkenyl, aryl or aryl(C-Cg)alkyl; wherein A is A’, straight chained or branched C;-C5 alkyl, aryl, heteroaryl, aryl(C;-Cg)alkyl or heteroaryl(C;-Cg)alkyl; wherein A' is
%, ~~ Poa el bye ER, wherein R; and R; are each independently H, straight chained or branched C;-C; alkyl, -F, --C, - -Br, --1, --NO,, or --CN; wherein Rj is H, straight chained or branched C;-C7 alkyl, --F, --Cl, -- Br, --1, --NO,, --CN, --OReg, aryl or heteroaryl; wherein Rs is straight chained or branched C;-C; alkyl, --N(R4)2, --OR4 or aryl; wherein Rg is straight chained or branched C;-C5 alkyl or aryl; wherein B is aryl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, indolizinyl, indol-4-yl, indo1-5-yl, indol-6-yl, indol-7-yl, isoindolyl, benzo[b]furan-4-yl, benzo[b]furan-5-yl, benzo[b]furan-6-yl, benzo[b]furan-7-yl, benzo[b]thiophen-4-yl, benzo[b]thiophen-5-yl, benzo[b]thiophen-6-yl, benzo[b]thiophen-7-yl, indazolyl, benzimidazolyl, benzo[b]thiazolyl, purinyl, imidazo[2,1-b]thiazolyl, quinolinyl, isoquinolinyl, quinazolinyl, 2,1,3-benzothiazolyl, furanyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, triazolyl, thiadiazolyl, benzoxazolyl, benzisoxazolyl, cinnolinyl, quinoxalinyl, 1,8- napthyridinyl, pteridinyl, or phthalimidyl; provided however, that the carbon atom or carbon atoms ortho to the nitrogen atom of the imine bond may only be substituted with one or more of the following --F, -Cl, --Br, --1, --CN, methyl, ethyl or methoxy; wherein n is an integer from 1 to 4 inclusive; wherein aryl is phenyl or napthyl, including phenyl and napthyl substituted with one or more of the following: -F, -Cl, -Br, -I, -NO,, -CN, straight chained or branched C;-C;
alkyl, straight chained or branched C;-C7; monofluoroalkyl, straight chained or branched C;-C polyfluoroalkyl, straight chained or branched C,-C7 alkenyl, straight chained or branched C,-C7 alkynyl, Cs-C; cycloalkyl, C;-C7 monofluorocycloalkyl, Cs-C7 polyfluorocycloalkyl, Cs-Cy cycloalkenyl, -OR4, SRy4, -OCORy, -COR4, -NCORy, -COzR4, -CON(R4); or (CH3),-O- (CH;)nCHs; or a pharmaceutically acceptable salt thereof.
70. The method of claim 52, wherein said memory agent is one or more selected from the group consisting of a compound having the structure: CF, CF, N / N OH or O (> NH CH; OcPent OMe wherein Me is methyl, cPent is cyclopentyl and the 3 and 5 carbons are in the S configuration.
71. A method comprising: testing a memory agent as a long term memory enhancer, wherein said testing comprises the steps of: administering said memory agent to a subject; presenting to said subject sets of stimuli; and evaluating said subject’s response to said stimuli.
72. The method of claim 71 wherein said sets of stimuli comprise a plurality of pairs of stimuli.
73. The method of claim 72 wherein each of said plurality of pairs of stimuli comprises a element that has an identifiable association with the other element of said pair.
74. The method of claim 73 wherein said identifiable association is selected from the group consisting of a face — name association and a word — word association.
75. The method of claim 71 wherein the second subject is an animal.
76. The method of claim 75, wherein the animal is a mammal.
17. The method of claim 76 wherein said mammal is selected from the group consisting of a primate, a mouse and a rat.
78. The method of claim 77, wherein said primate is selected from the group consisting of a human, a monkey, a lemur, a macaque and an ape.
79. The method of claim 78 wherein said primate is a human.
80. The method of claim 71 wherein said subject is a plurality of subjects.
81. The method of claim 80 wherein said plurality of subjects comprises a control group and an experimental group.
82. The method of claim 81 wherein said assessing comprises comparing said control group to said experimental group.
83. The method of claim 71, wherein said memory agent is one or more selected from the group consisting of a compound having the structure:
® . Lf Fe Ny he wt, ] E ¥ \ wherein each of Yi, Y», Y3, and Y4 is independently --H; straight chained or branched C;-C; alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C,-C7 alkenyl or alkynyl; Cs-C7 cycloalkyl or Cs-C7 cycloalkenyl; --F, --Cl1, --Br, or --1; --NO»; --N3; --CN; --ORy, --SRy4, --OCORy, --CORy, --NCORy, --N(R4)2, --CON(R4)2, or --COORy; aryl or heteroaryl; or any two of Yy, Y,, Y3 and Y, present on adjacent carbon atoms can constitute a methylenedioxy group; wherein each Ry is independently --H; straight chained or branched C;-C; alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C,-C7 alkenyl or alkynyl; Cs- C7 cycloalkyl, Cs-C7 cycloalkenyl, aryl or aryl(C-Cg)alkyl; wherein A is A’, straight chained or branched C;-C7 alkyl, aryl, heteroaryl, aryl(C;-Cg)alkyl or heteroaryl(C;-Ce)alkyl; wherein A' is a i ; Ng k ; ik 0 AN § A Eg) EY bh Te Hy LY L By “a, PN POAT ef bp REE R BR org, '
wherein R; and R; are each independently H, straight chained or branched C;-C; alkyl, -F, --C, - -Br, --1, --NO,, or --CN; wherein Rj is H, straight chained or branched C;-C7 alkyl, --F, --Cl, -- Br, --1, --NO,, --CN, --OReg, aryl or heteroaryl; wherein Rs is straight chained or branched C;-C; alkyl, --N(R4)2, --OR4 or aryl; wherein Rg is straight chained or branched C;-C5 alkyl or aryl; wherein B is aryl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, indolizinyl, indol-4-yl, indo1-5-yl, indol-6-yl, indol-7-yl, isoindolyl, benzo[b]furan-4-yl, benzo[b]furan-5-yl, benzo[b]furan-6-yl, benzo[b]furan-7-yl, benzo[b]thiophen-4-yl, benzo[b]thiophen-5-yl, benzo[b]thiophen-6-yl, benzo[b]thiophen-7-yl, indazolyl, benzimidazolyl, benzo[b]thiazolyl, purinyl, imidazo[2,1-b]thiazolyl, quinolinyl, isoquinolinyl, quinazolinyl, 2,1,3-benzothiazolyl, furanyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, triazolyl, thiadiazolyl, benzoxazolyl, benzisoxazolyl, cinnolinyl, quinoxalinyl, 1,8- napthyridinyl, pteridinyl, or phthalimidyl; provided however, that the carbon atom or carbon atoms ortho to the nitrogen atom of the imine bond may only be substituted with one or more of the following --F, -Cl, --Br, --1, --CN, methyl, ethyl or methoxy; wherein n is an integer from 1 to 4 inclusive; wherein aryl is phenyl or napthyl, including phenyl and napthyl substituted with one or more of the following: -F, -Cl, -Br, -I, -NO,, -CN, straight chained or branched C;-C7 alkyl, straight chained or branched C;-C; monofluoroalkyl, straight chained or branched C;-C5; polyfluoroalkyl, straight chained or branched C,-C7 alkenyl, straight chained or branched C,-C7 alkynyl, Cs-C; cycloalkyl, C;-C7 monofluorocycloalkyl, Cs-C7 polyfluorocycloalkyl, Cs-Cy cycloalkenyl, -OR4, SRy4, -OCORy, -COR4, -NCORy, -COzR4, -CON(R4); or (CH3),-O- (CH;)mCHs; or a pharmaceutically acceptable salt thereof.
84. The method of claim 71, wherein said memory agent is one or more selected from the group consisting of a compound having the structure: CF, CF, N / N O ® NH CH; OcPent OMe wherein Me is methyl, cPent is cyclopentyl and the 3 and 5 carbons are in the S configuration.
85. A system comprising: sets of stimuli, wherein said sets of stimuli are configured to permit evaluation of a subject’s response to said sets of stimuli and thereby assess the effectiveness of a memory agent administered to said subject.
86. The system of claim 85 wherein said sets of stimuli comprise a plurality of pairs of stimuli.
87. The system of claim 86 wherein each of said plurality of pairs of stimuli comprises a positive element or a negative element.
88. The system of claim 86 wherein each of said plurality of pairs of stimuli comprises an element that has an identifiable association with the other element of said pair.
89. The system of claim 88 wherein said identifiable association is selected from the group consisting of a face — name association and a word — word association.
90. The system of claim 85 wherein said subject is an animal.
91. The system of claim 90 wherein said animal is a mammal.
92. The system of claim 91 wherein said mammal is selected from the group consisting of a primate, a mouse and a rat.
93. The method of claim 92 wherein said primate is selected from the group consisting of a human, a monkey, a lemur, a macaque and an ape.
94. The method of claim 93 wherein said primate is a human.
95. The system of claim 85 wherein said subject is a plurality of subjects.
96. The system of claim 95 wherein said plurality of subjects comprises a control group and an experimental group.
97. The system of claim 96 wherein said assessing comprises comparing said control group to said experimental group.
98. The system of claim 85, wherein said memory agent is one or more selected from the group consisting of a compound having the structure:
ji I > wm) wherein each of Yi, Y,, Y3, and Yy is independently --H; straight chained or branched C;-C; alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C,-C7 alkenyl or alkynyl; Cs-C7 cycloalkyl or Cs-C7 cycloalkenyl; --F, --Cl1, --Br, or --1; --NO»; --N3; --CN; --ORy, --SRy4, --OCORy, --CORy, --NCORy, --N(R4)2, --CON(R4)2, or --COORy; aryl or heteroaryl; or any two of Yy, Y,, Y3 and Y, present on adjacent carbon atoms can constitute a methylenedioxy group; wherein each Ry is independently --H; straight chained or branched C;-C; alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C,-C7 alkenyl or alkynyl; Cs- C7 cycloalkyl, Cs-C7 cycloalkenyl, aryl or aryl(C-Cg)alkyl; wherein A is A’, straight chained or branched C;-C7 alkyl, aryl, heteroaryl, aryl(C;-Cg)alkyl or heteroaryl(C;-Ce)alkyl; wherein A' is a i
Sn por (OH EE wherein R; and R; are each independently H, straight chained or branched C;-C; alkyl, -F, --C, - -Br, --1, --NO,, or --CN; wherein Rj is H, straight chained or branched C;-C7 alkyl, --F, --Cl, --
Br, --1, --NO,, --CN, --OReg, aryl or heteroaryl; wherein Rs is straight chained or branched C;-C; alkyl, --N(R4)2, --OR4 or aryl; wherein Rg is straight chained or branched C;-C5 alkyl or aryl; wherein B is aryl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, indolizinyl, indol-4-yl, indo1-5-yl, indol-6-yl, indol-7-yl, isoindolyl, benzo[b]furan-4-yl, benzo[b]furan-5-yl, benzo[b]furan-6-yl, benzo[b]furan-7-yl, benzo[b]thiophen-4-yl, benzo[b]thiophen-5-yl, benzo[b]thiophen-6-yl, benzo[b]thiophen-7-yl, indazolyl, benzimidazolyl, benzo[b]thiazolyl, purinyl, imidazo[2,1-b]thiazolyl, quinolinyl, isoquinolinyl, quinazolinyl, 2,1,3-benzothiazolyl, furanyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, triazolyl, thiadiazolyl, benzoxazolyl, benzisoxazolyl, cinnolinyl, quinoxalinyl, 1,8- napthyridinyl, pteridinyl, or phthalimidyl; provided however, that the carbon atom or carbon atoms ortho to the nitrogen atom of the imine bond may only be substituted with one or more of the following --F, -Cl, --Br, --1, --CN, methyl, ethyl or methoxy; wherein n is an integer from 1 to 4 inclusive; wherein aryl is phenyl or napthyl, including phenyl and napthyl substituted with one or more of the following: -F, -Cl, -Br, -I, -NO,, -CN, straight chained or branched C;-C7 alkyl, straight chained or branched C;-C; monofluoroalkyl, straight chained or branched C;-C5; polyfluoroalkyl, straight chained or branched C,-C7 alkenyl, straight chained or branched C,-C7 alkynyl, Cs-C; cycloalkyl, C;-C7 monofluorocycloalkyl, Cs-C7 polyfluorocycloalkyl, Cs-Cy cycloalkenyl, -OR4, SRy4, -OCORy, -COR4, -NCORy, -COzR4, -CON(R4); or (CH3),-O- (CH;)mCHs; or a pharmaceutically acceptable salt thereof.
99. The system of claim 85 wherein said memory agent is one or more selected from the group consisting of a compound having the structure:
CF, CF, O / N Cok OH or O ® NT CH; we OMe wherein Me is methyl, cPent is cyclopentyl and the 3 and 5 carbons are in the S configuration.
100. A method comprising the steps of: assessing the effectiveness of a training protocol administered to a subject, wherein said assessing comprises presenting to said subject sets of stimuli and evaluating said subject’s response to said stimuli.
101. A method comprising: testing a training protocol as a long term memory enhancer, wherein said testing comprises the steps of: administering a training protocol to a subject; and presenting to said subject sets of stimuli and evaluating said subject’s response to said stimuli.
102. A system comprising: sets of stimuli, wherein said sets of stimuli are configured to permit evaluation of a subject’s response to said sets of stimuli and thereby assess the effectiveness of a training protocol administered to said subject.
103. The system of claim 102 wherein said sets of stimuli comprise a plurality of pairs of stimuli.
104. The system of claim 103 wherein each of said plurality of pairs of stimuli comprises a positive element or a negative element.
105. The system of claim 103 wherein each of said plurality of pairs of stimuli comprises an element that has an identifiable association with the other element of said pair.
106. The system of claim 105 wherein said identifiable association is selected from the group consisting of a face — name association and a word — word association.
107. A method comprising the steps of: assessing the effectiveness of a memory impairer administered to a subject, wherein said assessing comprises presenting to said subject sets of stimuli and evaluating said subject’s response to said stimuli.
108. The method of claim 107 wherein said sets of stimuli comprise a plurality of pairs of stimuli.
109. The method of claim 108 wherein each of said plurality of pairs of stimuli comprises a positive element or a negative element.
110. The method of claim 108 wherein each of said plurality of pairs of stimuli comprises a element that has an identifiable association with the other element of said pair.
111. The method of claim 110 wherein said identifiable association is selected from the group consisting of a face — name association and a word — word association.
112. The method of claim 107 wherein said subject is an animal.
113. The method of claim 112 wherein the animal is a mammal
114. The method of claim 113 wherein said mammal is selected from the group consisting of a primate, a mouse and a rat.
115. The method of claim 114 wherein said primate is selected from the group consisting of a human, a monkey, a lemur, a macaque and an ape.
116. The method of claim 115 wherein said primate is a human.
117. The method of claim 107 wherein said subject is a plurality of subjects.
118. The method of claim 117 wherein said plurality of subjects comprises a control group and an experimental group.
119. The method of claim 118 wherein said assessing comprises comparing said control group to said experimental group.
120. A method comprising: selecting a memory impairer as a drug candidate, wherein said selecting comprises the steps of: assessing said memory impairer by administering said memory impairer to a subject; and presenting to said subject sets of stimuli and evaluating said subject’s response to said stimuli.
121. The method of claim 120 wherein said sets of stimuli comprise a plurality of pairs of stimuli.
122. The method of claim 121 wherein each of said plurality of pairs of stimuli comprises a positive element or a negative element.
123. The method of claim 121 wherein each of said plurality of pairs of stimuli comprises an element that has an identifiable association with the other element of said pair.
124. The method of claim 123 wherein said identifiable association is selected from the group consisting of a face — name association and a word — word association.
125. The method of claim 120 wherein the subject is an animal.
126. The method of claim 125, wherein said animal is a mammal.
127. The method of claim 126 wherein said mammal is selected from the group consisting of a primate, a mouse and a rat.
128. The method of claim 127 wherein said primate is selected from the group consisting of a human, a monkey, a lemur, a macaque and an ape.
129. The method of claim 128 wherein said primate is a human.
130. The method of claim 120 wherein said subject is a plurality of subjects.
131. The method of claim 130 wherein said plurality of subjects comprises a control group and an experimental group.
132. The method of claim 131 wherein said assessing comprises comparing said control group to said experimental group.
133. A system comprising: sets of stimuli, wherein said sets of stimuli are configured to permit evaluation of a subject’s response to said sets of stimuli and thereby assess the effectiveness of a memory impairer administered to said subject.
134. The system of claim 133 wherein said sets of stimuli comprise a plurality of pairs of stimuli.
135. The system of claim 134 wherein each of said plurality of pairs of stimuli comprises a positive element or a negative element.
136. The system of claim 134 wherein each of said plurality of pairs of stimuli comprises an element that has an identifiable association with the other element of said pair.
137. The system of claim 136 wherein said identifiable association is selected from the group consisting of a face — name association and a word — word association.
138. The system of claim 133 wherein the subject is an animal.
139. The sysetm of claim 138, wherein said animal is a mammal.
140. The system of claim 139 wherein said mammal is selected from the group consisting of a primate, a mouse and a rat.
141. The system of claim 140 wherein said primate is selected from the group consisting of a human, a monkey, a lemur, a macaque and an ape.
142. The system of claim 141 wherein said primate is a human.
143. The system of claim 133 wherein said subject is a plurality of subjects.
144. The system of claim 143 wherein said plurality of subjects comprises a control group and an experimental group.
145. The system of claim 144 wherein said assessing comprises comparing said control group to said experimental group.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8194508P | 2008-07-18 | 2008-07-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG195572A1 true SG195572A1 (en) | 2013-12-30 |
Family
ID=41550744
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG2013077730A SG195572A1 (en) | 2008-07-18 | 2009-07-17 | Methods and systems for evaluating memory agents |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP2313098A4 (en) |
JP (1) | JP5789511B2 (en) |
KR (1) | KR20110049801A (en) |
CN (1) | CN102143749A (en) |
AU (1) | AU2009270697A1 (en) |
BR (1) | BRPI0916228A2 (en) |
CA (1) | CA2730940A1 (en) |
IL (1) | IL210696A (en) |
MX (1) | MX2011000652A (en) |
SG (1) | SG195572A1 (en) |
WO (1) | WO2010009453A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8277842B1 (en) | 2012-01-20 | 2012-10-02 | Dart Neuroscience (Cayman) Ltd. | Enteric-coated HT-2157 compositions and methods of their use |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6770658B2 (en) * | 1998-09-09 | 2004-08-03 | Inflazyme Pharmaceuticals Ltd. | Substituted γ-phenyl-Δ-lactams and uses related thereto |
EP1161525A2 (en) * | 1999-03-12 | 2001-12-12 | Brown University Research Foundation | Methods and compositions for regulating memory consolidation |
ES2323940T3 (en) * | 2000-05-01 | 2009-07-28 | Accera, Inc. | USE OF MEDIUM CHAIN TRIGLICERIDS FOR THE TREATMENT AND PREVENTION OF ALZHEIMER'S DISEASE. |
US20070179197A1 (en) * | 2000-05-01 | 2007-08-02 | Accera, Inc. | Compositions and methods for improving or preserving brain function |
JP2002020291A (en) * | 2000-06-30 | 2002-01-23 | Sumitomo Pharmaceut Co Ltd | Therapeutic agent for cognitive dysfunction |
WO2002013867A2 (en) * | 2000-08-10 | 2002-02-21 | Cold Spring Harbor Laboratory | Augmented cognitive training |
US20040224316A1 (en) * | 2000-08-10 | 2004-11-11 | Tully Timothy P. | Augmented cognitive training |
EP1551855B1 (en) * | 2002-06-25 | 2012-01-04 | Helicon Therapeutics, Inc. | Altering memory by affecting staufen function |
US7642281B2 (en) * | 2002-08-07 | 2010-01-05 | Helicon Therapeutics, Inc. | Indolone compounds useful to treat cognitive impairment |
AU2003258287A1 (en) * | 2002-08-19 | 2004-03-03 | Helicon Therapeutics, Inc. | Screening methods for cognitive enhancers |
AU2006326040B2 (en) * | 2005-12-15 | 2012-02-09 | Société des Produits Nestlé S.A. | Compositions and methods for preserving brain function |
EP2001293B9 (en) * | 2006-04-03 | 2019-04-17 | Accera, Inc. | Use of ketogenic compounds for treatment of age-associated memory impairment |
SG172602A1 (en) * | 2006-05-19 | 2011-07-28 | Helicon Therapeutics Inc | Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation |
GB0611458D0 (en) * | 2006-06-09 | 2006-07-19 | Univ Cambridge Tech | Assessment of functional status |
JP2009541493A (en) * | 2006-06-26 | 2009-11-26 | ヘリコン セラピューティクス,インコーポレイテッド | Method for modulating neurite outgrowth by use of a galanin-3 receptor antagonist |
-
2009
- 2009-07-17 CA CA2730940A patent/CA2730940A1/en not_active Abandoned
- 2009-07-17 AU AU2009270697A patent/AU2009270697A1/en not_active Abandoned
- 2009-07-17 KR KR1020117003456A patent/KR20110049801A/en not_active Application Discontinuation
- 2009-07-17 BR BRPI0916228A patent/BRPI0916228A2/en not_active IP Right Cessation
- 2009-07-17 JP JP2011518952A patent/JP5789511B2/en not_active Expired - Fee Related
- 2009-07-17 WO PCT/US2009/051082 patent/WO2010009453A1/en active Application Filing
- 2009-07-17 MX MX2011000652A patent/MX2011000652A/en not_active Application Discontinuation
- 2009-07-17 EP EP20090798843 patent/EP2313098A4/en not_active Ceased
- 2009-07-17 SG SG2013077730A patent/SG195572A1/en unknown
- 2009-07-17 CN CN2009801347276A patent/CN102143749A/en active Pending
-
2011
- 2011-01-17 IL IL210696A patent/IL210696A/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
EP2313098A4 (en) | 2011-12-21 |
IL210696A0 (en) | 2011-03-31 |
MX2011000652A (en) | 2011-06-16 |
IL210696A (en) | 2014-12-31 |
AU2009270697A1 (en) | 2010-01-21 |
CN102143749A (en) | 2011-08-03 |
WO2010009453A1 (en) | 2010-01-21 |
JP2011528667A (en) | 2011-11-24 |
EP2313098A1 (en) | 2011-04-27 |
KR20110049801A (en) | 2011-05-12 |
JP5789511B2 (en) | 2015-10-07 |
CA2730940A1 (en) | 2010-01-21 |
BRPI0916228A2 (en) | 2015-11-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8455538B2 (en) | Augmented cognitive training | |
US9408830B2 (en) | Phosphodiesesterase 4 inhibitors for the treatment of a cognitive deficit | |
US20100028839A1 (en) | Methods and systems for evaluating memory agents | |
US9931318B2 (en) | Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation | |
CA2653042C (en) | Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation | |
EP2156831B1 (en) | HT0712 for treating a cognitive deficit | |
US9795591B2 (en) | Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation | |
SG195572A1 (en) | Methods and systems for evaluating memory agents |